Hematologic disorder
MONDO:0005570A disease involving the hematopoietic system.
Also known as: blood disease, blood disorder, disease of hematopoietic system, disease of the blood and blood-forming organs, disease or disorder of haematopoietic system, disease or disorder of hematopoietic system, disorder of haematopoietic system, disorder of hematopoietic system
8525 clinical trials for this condition and its sub-types, 176 tagged with Hematologic disorder itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Hematologic disorder
-
Hematopoietic and lymphoid system neoplasm 692 trials · 6,335 incl. sub-types
9 sub-types
- Hematopoietic and lymphoid cell neoplasm 486 trials · 5,943 incl. sub-types Sub-types →
- Lymphoid hemopathy 0 trials · 4,285 incl. sub-types Sub-types →
- Myeloid hemopathy 0 trials · 1,765 incl. sub-types Sub-types →
- Bone marrow neoplasm 3 trials · 1,633 incl. sub-types Sub-types →
- Thymus neoplasm 5 trials · 240 incl. sub-types Sub-types →
- Spleen neoplasm 0 trials · 232 incl. sub-types Sub-types →
- Lymph node neoplasm 5 trials · 60 incl. sub-types Sub-types →
- STAT3-related early-onset multisystem autoimmune disease 2 trials
- Cavernous hemangioma 1 trial Sub-types →
-
Leukocyte disorder 6 trials · 3,581 incl. sub-types
23 sub-types
- B-cell neoplasm 305 trials · 3,174 incl. sub-types Sub-types →
- T-cell leukemia 9 trials · 137 incl. sub-types Sub-types →
- B cell deficiency 5 trials · 86 incl. sub-types Sub-types →
- Leukopenia 6 trials · 78 incl. sub-types Sub-types →
- Dendritic cell sarcoma 0 trials · 53 incl. sub-types Sub-types →
- Eosinophil disorder 2 trials · 51 incl. sub-types Sub-types →
- Langerhans cell histiocytosis 40 trials · 41 incl. sub-types Sub-types →
- Phagocyte bactericidal dysfunction 0 trials · 37 incl. sub-types Sub-types →
- Mastocytosis 15 trials · 34 incl. sub-types Sub-types →
- Functional neutrophil defect 0 trials · 13 incl. sub-types Sub-types →
- Mast cell activation syndrome 8 trials · 9 incl. sub-types Sub-types →
- POEMS syndrome 8 trials
- Subcutaneous panniculitis-like T-cell lymphoma 8 trials
- EBV-positive T-cell lymphoproliferative disorder of childhood 3 trials · 7 incl. sub-types Sub-types →
- Thymoma type B 0 trials · 4 incl. sub-types Sub-types →
- Human granulocytic anaplasmosis 1 trial
- Pelger-Huet anomaly 0 trials
- Eosinophil peroxidase deficiency 0 trials
- Hereditary neutrophilia 0 trials
- Human monocytic ehrlichiosis 0 trials
- Leukostasis 0 trials
- Pituitary gland basophil adenoma 0 trials
- Small intestinal enteropathy-associated T-cell lymphoma 0 trials
-
Bone marrow disorder 18 trials · 1,763 incl. sub-types
7 sub-types
- Bone marrow neoplasm 3 trials · 1,633 incl. sub-types Sub-types →
- Polycythemia 9 trials · 99 incl. sub-types Sub-types →
- Bone marrow failure syndrome 48 trials Sub-types →
- Osteomyelitis 43 trials · 46 incl. sub-types Sub-types →
- Fanconi anemia 29 trials · 42 incl. sub-types Sub-types →
- Drachtman Weinblatt Sitarz syndrome 0 trials
- Premature ovarian failure 15 0 trials
-
Anemia 258 trials · 975 incl. sub-types
19 sub-types
- Aplastic anemia 110 trials · 411 incl. sub-types Sub-types →
- Normocytic anemia 0 trials · 180 incl. sub-types Sub-types →
- Microcytic anemia 0 trials · 130 incl. sub-types Sub-types →
- Hypochromic anemia 0 trials · 123 incl. sub-types Sub-types →
- Beta-thalassemia and related diseases 0 trials · 99 incl. sub-types Sub-types →
- Congenital anemia 0 trials · 58 incl. sub-types Sub-types →
- Anemia due to chronic disorder 34 trials
- Pure red-cell aplasia 5 trials · 24 incl. sub-types Sub-types →
- Neonatal anemia 7 trials · 23 incl. sub-types Sub-types →
- Deficiency anemia 3 trials · 16 incl. sub-types Sub-types →
- Pancytopenia 15 trials
- Anemia due to enzyme disorder 1 trial · 14 incl. sub-types Sub-types →
- Sideroblastic anemia 0 trials · 14 incl. sub-types Sub-types →
- Macrocytic anemia 0 trials · 11 incl. sub-types Sub-types →
- Hemoglobin C disease 2 trials
- Hereditary methemoglobinemia 0 trials · 1 incl. sub-types Sub-types →
- Hemoglobin D disease 0 trials
- Hemoglobin E disease 0 trials
- Hemoglobinopathy Toms River 0 trials
-
Erythrocyte disorder 7 trials · 618 incl. sub-types
2 sub-types
- Hemoglobinopathy 34 trials · 446 incl. sub-types Sub-types →
- Malaria 135 trials · 170 incl. sub-types Sub-types →
-
Blood coagulation disease 54 trials · 541 incl. sub-types
8 sub-types
- Inherited blood coagulation disorder 8 trials · 323 incl. sub-types Sub-types →
- Coagulation protein disease 13 trials · 274 incl. sub-types Sub-types →
- Thrombotic microangiopathy 26 trials · 151 incl. sub-types Sub-types →
- Thrombophilia 12 trials · 75 incl. sub-types Sub-types →
- Hemolytic-uremic syndrome 7 trials · 24 incl. sub-types Sub-types →
- Hemorrhagic disease of newborn 1 trial
- Marantic endocarditis 0 trials
- Prekallikrein deficiency 0 trials Sub-types →
-
Hemorrhagic disease 108 trials · 510 incl. sub-types
28 sub-types
- Hemophilia A 180 trials Sub-types →
- Purpura 4 trials · 117 incl. sub-types Sub-types →
- Hemophilia B 84 trials · 91 incl. sub-types Sub-types →
- Vascular hemostatic disease 62 trials · 63 incl. sub-types Sub-types →
- Hereditary von Willebrand disease 18 trials · 29 incl. sub-types Sub-types →
- Inherited bleeding disorder, platelet-type 6 trials · 26 incl. sub-types Sub-types →
- Acquired hemophilia 2 trials · 8 incl. sub-types Sub-types →
- Congenital fibrinogen deficiency 2 trials · 6 incl. sub-types Sub-types →
- Factor VII deficiency 6 trials Sub-types →
- Congenital vitamin K-dependent coagulation factors deficiency 0 trials · 4 incl. sub-types Sub-types →
- Fetal and neonatal alloimmune thrombocytopenia 4 trials Sub-types →
- Acquired von willebrand syndrome 3 trials
- Factor X deficiency 2 trials Sub-types →
- Congenital factor XII deficiency 1 trial
- Congenital plasminogen activator inhibitor type 1 deficiency 1 trial
- East Texas bleeding disorder 0 trials
- Alpha-2-plasmin inhibitor deficiency 0 trials
- Combined deficiency of factor V and factor VIII 0 trials Sub-types →
- Congenital factor V deficiency 0 trials
- Congenital factor XI deficiency 0 trials
- Congenital factor XIII deficiency 0 trials Sub-types →
- Congenital high-molecular-weight kininogen deficiency 0 trials
- Hemophilia B leyden 0 trials
- Hemorrhagic disease due to alpha-1-antitrypsin Pittsburgh mutation 0 trials
- Inherited prekallikrein deficiency 0 trials
- Multiple sclerosis-ichthyosis-factor VIII deficiency syndrome 0 trials
- Prothrombin deficiency 0 trials Sub-types →
- Thrombomodulin-related bleeding disorder 0 trials
-
Blood platelet disease 18 trials · 370 incl. sub-types
5 sub-types
- Thrombocytopenia 75 trials · 267 incl. sub-types Sub-types →
- Thrombocytosis disease 7 trials · 71 incl. sub-types Sub-types →
- Inherited bleeding disorder, platelet-type 6 trials · 26 incl. sub-types Sub-types →
- Qualitative platelet defect 6 trials
- TPM4-related platelet disorder 0 trials
-
Splenic disorder 3 trials · 248 incl. sub-types
8 sub-types
- Spleen neoplasm 0 trials · 232 incl. sub-types Sub-types →
- Hypersplenism 12 trials
- Splenic sequestration 1 trial
- Congestive splenomegaly 0 trials Sub-types →
- Splenic abscess 0 trials
- Splenic infarction 0 trials
- Splenic tuberculosis 0 trials
- Wandering spleen 0 trials
-
Thymus gland disorder 1 trial · 240 incl. sub-types
3 sub-types
- Thymus neoplasm 5 trials · 240 incl. sub-types Sub-types →
- Ectopic thymus 0 trials
- Thymic dysplasia 0 trials
-
Autoimmune disorder of blood 0 trials · 152 incl. sub-types
2 sub-types
- Primary thrombocytopenia 27 trials · 110 incl. sub-types Sub-types →
- Autoimmune hemolytic anemia 49 trials · 72 incl. sub-types Sub-types →
-
Congenital hematological disorder 1 trial · 101 incl. sub-types
21 sub-types
- Congenital anemia 0 trials · 58 incl. sub-types Sub-types →
- Constitutional neutropenia 2 trials · 28 incl. sub-types Sub-types →
- Congenital thrombotic thrombocytopenic purpura 5 trials
- Congenital vitamin K-dependent coagulation factors deficiency 0 trials · 4 incl. sub-types Sub-types →
- GNE myopathy 3 trials
- Congenital amegakaryocytic thrombocytopenia 1 3 trials
- Leukocyte adhesion deficiency type II 2 trials
- Congenital factor XII deficiency 1 trial
- Congenital plasminogen activator inhibitor type 1 deficiency 1 trial
- Thrombocytopenia-absent radius syndrome 1 trial
- Congenital agammaglobulinemia 0 trials Sub-types →
- Congenital analbuminemia 0 trials
- Congenital factor XI deficiency 0 trials
- Congenital factor XIII deficiency 0 trials Sub-types →
- Congenital progressive bone marrow failure-B-cell immunodeficiency-skeletal dysplasia syndrome 0 trials
- Congenital secondary polycythemia 0 trials Sub-types →
- Hereditary thrombocytosis with transverse limb defect 0 trials
- Hypercoagulability syndrome due to glycosylphosphatidylinositol deficiency 0 trials
- Macrothrombocytopenia-lymphedema-developmental delay-facial dysmorphism-camptodactyly syndrome 0 trials
- Radio-ulnar synostosis-amegakaryocytic thrombocytopenia syndrome 0 trials Sub-types →
- Sulfhemoglobinemia, congenital 0 trials
-
Monoclonal gammopathy 24 trials · 68 incl. sub-types
3 sub-types
-
Premalignant hematological system disease 3 trials · 25 incl. sub-types
2 sub-types
- Clonal hematopoiesis 10 trials · 22 incl. sub-types Sub-types →
- Atypical lymphoproliferative disorder 0 trials
-
Paraneoplastic hematological syndrome 0 trials · 9 incl. sub-types
2 sub-types
- POEMS syndrome 8 trials
- Humoral hypercalcemia of malignancy 1 trial
-
Parasitemia 5 trials
-
Blood group incompatibility 2 trials
1 sub-type
- Rh isoimmunization 0 trials
-
L-ferritin deficiency 1 trial
-
Hyperamylasemia 1 trial
-
Bloom syndrome 0 trials
-
GATA1-Related X-Linked Cytopenia 0 trials
-
Polyclonal hyperviscosity syndrome 0 trials
-
Septicemic plague 0 trials
Most studied deeper sub-types
Showing the 400 most recently updated of 1065 trials in this tab.
-
Half-Matched stem cell transplants tested as a cure path for older aplastic anemia patients
Cure Not yet recruitingResearchers are testing a conditioning regimen built around thiotepa before a haploidentical, or half-matched, stem cell transplant in people aged 50 and older with severe aplastic anemia. The regimen also includes busulfan, fludarabine, anti-thymocyte globulin, and basiliximab, …
Sponsor: Peking University People's Hospital • Aim: Cure
Last updated Sep 21, 2026 20:00 UTC
-
Experimental therapy SNC116 put to the test against Hard-to-Treat leukemia
Cure Not yet recruitingResearchers are testing an experimental therapy called SNC116 in adults with B-cell acute lymphoblastic leukemia that has returned or stopped responding to treatment. The early-stage study enrolls about 28 people and focuses on safety, side effects, and how the body processes the…
Early phase 1 • Sponsor: Shanghai Simnova Biotechnology Co.,Ltd. • Aim: Cure
Last updated Sep 21, 2026 20:00 UTC
-
Experimental cell therapy targets Hard-to-Treat lymphoma
Cure Not yet recruitingResearchers are testing an experimental cell therapy called CT1190B in adults with large B-cell lymphoma that has returned or stopped responding to treatment. The trial enrolls up to 68 people aged 18 to 75 and gives the therapy by intravenous infusion. The main goals are to chec…
Phase 1/2 • Sponsor: UCARsgen Biotech Limited • Aim: Cure
Last updated Sep 18, 2026 00:00 UTC
-
Ancient herb put to the test against hidden malaria
Cure Not yet recruitingResearchers in Gabon are testing whether a tea made from dried Artemisia annua leaves can clear malaria parasites in adults who carry the infection without feeling sick. The trial enrolls 20 semi-immune adults aged 18 to 45 who have low levels of Plasmodium falciparum in their bl…
Phase 1 • Sponsor: Centre de Recherche Médicale de Lambaréné • Aim: Cure
Last updated Sep 17, 2026 00:00 UTC
-
Donor CAR-T cells aim to reset a misguided immune system
Cure Not yet recruitingResearchers are testing a new cell therapy called CHT105 in up to 24 adults with relapsed or refractory autoimmune diseases, including immune thrombocytopenia (ITP). CHT105 uses donor-derived CAR-T cells engineered to target two markers, CD19 and CD70, on immune cells. The goal i…
Sponsor: Nanjing Miracle Biotechnology Co., Ltd. • Aim: Cure
Last updated Sep 12, 2026 00:00 UTC
-
Could bone marrow from deceased donors cure blood cancers?
Cure Not yet recruitingThis study tests whether bone marrow from deceased donors can be used to treat people with blood cancers like leukemia and lymphoma. Participants receive a transplant of cryopreserved marrow from a deceased donor or standard cells from a living donor. The goal is to see if the de…
Sponsor: Ossium Health, Inc. • Aim: Cure
Last updated Sep 12, 2026 00:00 UTC
-
Off-the-Shelf CAR-T cells target a marker on stubborn blood cancers
Cure Not yet recruitingResearchers are testing an experimental cell therapy called CHT101 in adults with T-cell or B-cell blood cancers that have returned or stopped responding to treatment. CHT101 uses donor-derived T cells engineered to recognize CD70, a marker found on these cancer cells. The phase …
Phase 1 • Sponsor: Nanjing Miracle Biotechnology Co., Ltd. • Aim: Cure
Last updated Sep 11, 2026 00:00 UTC
-
Off-the-Shelf CAR-T cells target CD70 in Hard-to-Treat blood cancers
Cure Not yet recruitingResearchers are testing CHT101, an experimental CAR-T cell therapy made from donor cells, in adults with T-cell or B-cell blood cancers that have come back or stopped responding to treatment. The therapy targets CD70, a marker found on these cancer cells. The Phase I trial aims t…
Phase 1 • Sponsor: Nanjing Miracle Biotechnology Co., Ltd. • Aim: Cure
Last updated Sep 11, 2026 00:00 UTC
-
Can a new drug combo make stem cell transplants safer for frail AML patients?
Cure Not yet recruitingThis trial is testing whether a new conditioning regimen, called VABu, can improve outcomes for adults with acute myeloid leukemia (AML) who are in first remission but are too frail for standard transplant prep. The regimen combines venetoclax, azacitidine (or decitabine), and bu…
Sponsor: The First Affiliated Hospital of Soochow University • Aim: Cure
Last updated Aug 21, 2026 00:00 UTC
-
Can a pill and injection combo beat AML without harsh chemo?
Cure Not yet recruitingThis trial tests a combination of two drugs, azacitidine and venetoclax, as the first treatment for young, fit adults (ages 18-50) with newly diagnosed acute myeloid leukemia (AML). The goal is to see how many patients achieve complete remission after one or two cycles of this th…
Phase 2 • Sponsor: Pakistan Blood and Marrow Transplant (PBMT) Group • Aim: Cure
Last updated Aug 07, 2026 00:00 UTC
-
One-shot CAR-T therapy takes on stem cell transplant for multiple myeloma
Cure Not yet recruitingThis phase 3 trial tests whether a single infusion of AZD0120, a CAR-T cell therapy that targets two proteins on myeloma cells, can outperform the standard approach of high-dose chemotherapy followed by a stem cell transplant. The study enrolls adults newly diagnosed with multipl…
Phase 3 • Sponsor: AstraZeneca • Aim: Cure
Last updated Aug 01, 2026 00:00 UTC
-
New malaria combo aims to stop relapses for good
Cure Not yet recruitingThis Phase 2b trial tests whether a new drug, SJ733, combined with tafenoquine can cure P. vivax malaria and prevent it from returning. About 104 adults with uncomplicated malaria will receive different schedules of SJ733 plus tafenoquine, or standard chloroquine plus tafenoquine…
Phase 2 • Sponsor: R. Kiplin Guy • Aim: Cure
Last updated Aug 01, 2026 00:00 UTC
-
Can a smart immune cell with a kill switch beat tough lymphomas?
Cure Not yet recruitingThis Phase 1 trial tests a new type of cell therapy for people with relapsed or refractory CD30-positive lymphomas, including Hodgkin lymphoma and certain non-Hodgkin lymphomas. The treatment uses a patient's own immune cells that are genetically engineered to recognize and attac…
Phase 1 • Sponsor: The Methodist Hospital Research Institute • Aim: Cure
Last updated Jul 29, 2026 00:00 UTC
-
Can a single infusion of engineered immune cells beat back hard-to-treat multiple myeloma?
Cure Not yet recruitingThis early-stage trial is testing an experimental therapy called KIV-318 for people with multiple myeloma that has returned or stopped responding to at least three prior treatments. KIV-318 is a type of CAR-T cell therapy that reprograms a patient's own immune cells to recognize …
Phase 1 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Cure
Last updated Jul 26, 2026 00:00 UTC
-
Can a fourth drug tip the scales against an aggressive leukemia?
Cure Not yet recruitingThis trial is testing whether adding venetoclax to standard intensive chemotherapy plus midostaurin can improve outcomes for adults with a type of acute myeloid leukemia that has a FLT3 mutation. The study enrolls people aged 18 to 70 with newly diagnosed disease who are healthy …
Phase 1/2 • Sponsor: University Hospital, Bordeaux • Aim: Cure
Last updated Jul 26, 2026 00:00 UTC
-
3-Day malaria cure could transform treatment
Cure Not yet recruitingThis study tests a shorter, higher-dose course of primaquine to cure vivax malaria and prevent it from coming back. Current treatments take too long, so a 3-day course could make it easier for patients to complete therapy. The trial involves over 1,000 people aged 5 and older wit…
Phase 3 • Sponsor: Menzies School of Health Research • Aim: Cure
Last updated Jun 27, 2026 11:00 UTC
-
Malaria vaccines put to the test: can three new shots trigger protection?
Vaccine Not yet recruitingResearchers are testing three experimental malaria vaccines (LYB014, LYB017, and LYB027) in healthy adults aged 18 to 50. Participants receive either a low or high dose of one vaccine combined with an immune-boosting adjuvant, or the adjuvant alone as a comparison. The trial trac…
Phase 1 • Sponsor: Guangzhou Patronus Biotech Co., Ltd. • Aim: Vaccine
Last updated Sep 21, 2026 20:00 UTC
-
New Self-Amplifying mRNA vaccine aims to better protect transplant patients against COVID-19
Vaccine Not yet recruitingThis study tests a new COVID-19 vaccine (LUNAR-COV19) in 56 adults who received a blood stem cell transplant within the past year. These patients often have weaker immune responses to standard vaccines. The new vaccine uses a self-amplifying mRNA that may produce a stronger and l…
Phase 2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Vaccine
Last updated Sep 19, 2026 00:00 UTC
-
Can a single shot of a genetically weakened malaria parasite train the body to fight off the real thing?
Vaccine Not yet recruitingThis trial tests a new malaria vaccine, PfSPZ-LARC2, made from live but genetically weakened malaria parasites that stop developing in the liver and never reach the bloodstream. The goal is to see if a single dose can safely and effectively protect healthy adults in Burkina Faso …
Phase 1 • Sponsor: Sanaria Inc. • Aim: Vaccine
Last updated Aug 02, 2026 00:00 UTC
-
New malaria vaccine candidate enters human trial in thailand
Vaccine Not yet recruitingThis phase II trial tests a new malaria vaccine called PvRII/Matrix-M in 36 healthy Thai adults aged 20-55. Half receive the vaccine, half a placebo. After three doses, 24 volunteers will be exposed to the malaria parasite in a controlled setting to see if the vaccine reduces inf…
Phase 2 • Sponsor: University of Oxford • Aim: Vaccine
Last updated Jun 27, 2026 12:00 UTC
-
New malaria vaccine trial aims to stop recurrent fever
Vaccine Not yet recruitingThis study tests an experimental vaccine called PvCS/Montanide ISA-51 to see if it can protect against P. vivax malaria, a major cause of recurrent fever and anemia. 72 healthy adults in Colombia will receive either the vaccine or a placebo, then be exposed to infected mosquitoes…
Phase 2 • Sponsor: Malaria Vaccine and Drug Development Center • Aim: Vaccine
Last updated Jun 27, 2026 09:00 UTC
-
Bispecific antibody combo aims to deepen myeloma responses
Disease control Not yet recruitingResearchers are testing whether CM336, a bispecific antibody that helps the immune system target myeloma cells, works safely and effectively when combined with daratumumab and lenalidomide. The trial enrolls adults aged 18 to 75 with newly diagnosed multiple myeloma who are not p…
Phase 2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Sep 21, 2026 20:00 UTC
-
Personalized stem cell transplant aims to beat inherited blood cancers
Disease control Not yet recruitingThis study tests whether adjusting chemotherapy doses for each patient can improve outcomes after a stem cell transplant for blood cancers caused by a RUNX1 gene mutation. Up to 98 people aged 4 to 70 with these cancers will receive a transplant from a half-matched donor. The goa…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 21, 2026 20:00 UTC
-
Triple drug combo targets myeloma that came back
Disease control Not yet recruitingResearchers are testing a combination of three drugs, belantamab mafodotin, cevostamab, and pomalidomide, in adults whose multiple myeloma has returned after at least two prior treatments. The phase 1b trial aims to find the best dose and see how well the combination controls the…
Phase 1 • Sponsor: Canadian Myeloma Research Group • Aim: Disease control
Last updated Sep 21, 2026 20:00 UTC
-
Engineered immune cells take aim at stubborn blood disorder
Disease control Not yet recruitingThis early-phase trial tests a new therapy called META 10-19 for people with autoimmune hemolytic anemia (AIHA) that has not responded to standard treatments. AIHA is a condition where the immune system mistakenly destroys red blood cells, causing anemia. META 10-19 uses a patien…
Early phase 1 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Sep 21, 2026 20:00 UTC
-
Experimental drug targets Hard-to-Treat leukemia in small early trial
Disease control Not yet recruitingThis early study tests an experimental drug called zeprumetostat in people with a rare type of leukemia (T-cell large granular lymphocyte leukemia) that has not responded to or has come back after other treatments. Ten participants take the drug twice daily for two 28-day cycles.…
Phase 1 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Sep 21, 2026 20:00 UTC
-
Can a lab-made antibody stop bleeding in a rare blood disorder?
Disease control Not yet recruitingResearchers are testing denecimig, an experimental antibody given as an injection under the skin, in adults newly diagnosed with acquired haemophilia A. This rare condition causes the immune system to attack a clotting protein, leading to sudden and sometimes severe bleeding. The…
Phase 3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Sep 21, 2026 20:00 UTC
-
Can a Platelet-Boosting drug speed recovery after stem cell transplant?
Disease control Not yet recruitingAfter an allogeneic stem cell transplant, patients often face weeks with dangerously low platelets and need frequent transfusions. This trial tests whether romiplostim, a drug that stimulates platelet production, helps platelets recover faster. Researchers randomly assign 87 adul…
Phase 2 • Sponsor: The First Affiliated Hospital of Henan University of Science and Technology • Aim: Disease control
Last updated Sep 21, 2026 20:00 UTC
-
Can a new pill outsmart Drug-Resistant leukemia?
Disease control Not yet recruitingThis phase 2 trial tests an oral drug called nemtabrutinib in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) whose cancer has stopped responding to other targeted therapies. Participants take nemtabrutinib once daily in 28-day cycles until the …
Phase 2 • Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Disease control
Last updated Sep 21, 2026 20:00 UTC
-
Triple-Drug combo aims to deepen myeloma response before transplant
Disease control Not yet recruitingResearchers are testing whether adding an experimental drug called F182112 to isatuximab and lenalidomide is safe and can help people with newly diagnosed multiple myeloma who are eligible for a stem cell transplant. The trial enrolls about 10 adults aged 18 to 70. Participants r…
Phase 2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Can text messages fight anemia? new trial tests digital nutrition for teens
Disease control Not yet recruitingThis study tests whether adding digital nutrition education—via SMS or group sessions—to daily micronutrient supplements can lower anemia rates in 1,200 adolescents aged 15-19 in Dar es Salaam, Tanzania. All participants get supplements and basic nutrition info; some also receive…
Sponsor: Harvard School of Public Health (HSPH) • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Can a liposomal drug combo improve AML treatment for older adults?
Disease control Not yet recruitingResearchers are testing a three-drug regimen called VAM for older or unfit adults with newly diagnosed acute myeloid leukemia (AML). The regimen combines liposomal mitoxantrone, azacitidine, and venetoclax. The trial aims to find the safest and most tolerable dose of liposomal mi…
Phase 1 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Can an injected biologic cut steroid Flare-Ups in a Tough-to-Treat asthma complication?
Disease control Not yet recruitingResearchers are studying depemokimab, an injected biologic drug, in adults aged 18 to 75 who have allergic bronchopulmonary aspergillosis (ABPA) along with severe eosinophilic asthma. The study tracks how many asthma attacks need systemic steroids and whether participants' qualit…
Sponsor: Qianfoshan Hospital • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Head-to-Head: which JAK inhibitor wins for myelofibrosis patients with low blood counts?
Disease control Not yet recruitingThis study compares two FDA-approved drugs, momelotinib and ruxolitinib, in people with myelofibrosis who also have low blood cell counts. The main goal is to see which drug does a better job at shrinking the spleen and reducing the need for blood transfusions. About 268 particip…
Phase 4 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Can a smaller dose of this cancer drug still work? new trial aims to find out
Disease control Not yet recruitingThis phase 2 trial is testing whether a lower dose of the immunotherapy drug nivolumab, given less often, can still control cancer in people with various advanced or metastatic cancers. The goal is to see if a cheaper, more accessible regimen works as well as the standard high-co…
Phase 2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
A common antioxidant may help platelets recover faster after stem cell transplant
Disease control Not yet recruitingThis trial tests whether the antioxidant N-acetylcysteine (NAC) can help platelets recover faster after a stem cell transplant in people with severe aplastic anemia. Participants take NAC capsules three times daily from two weeks before transplant until two months after. The stud…
Phase 3 • Sponsor: Peking University People's Hospital • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Iron and folic acid: a simple pill that could ease anemia and heart symptoms?
Disease control Not yet recruitingThis observational study is looking at whether Ferretab comp., an oral iron and folic acid supplement, can improve anemia and heart-related symptoms in adults who also have coronary artery disease or heart failure. Participants take the supplement for 12 weeks as part of their us…
Sponsor: Alcea • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Leukemia shot could replace long IV drips
Disease control Not yet recruitingThis study tests if a shot (subcutaneous) of the drug blinatumomab works as well as the standard IV drip for adults with a certain type of leukemia (Ph-negative B-cell ALL). About 560 people who are in remission after initial chemo will get either the shot or the IV, along with m…
Phase 3 • Sponsor: Amgen • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New drug BL-M08D1 joins standard therapy in fight against aggressive lymphoma
Disease control Not yet recruitingResearchers are testing an experimental drug called BL-M08D1 alongside standard immunochemotherapy in adults with diffuse large B-cell lymphoma. The trial enrolls about 204 people aged 18 to 75 whose cancer has at least one measurable lesion. Participants receive BL-M08D1 plus a …
Phase 1/2 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Leukemia combo shot and pill shows promise in early trial
Disease control Not yet recruitingThis Phase 2 trial tests a combination of two drugs—blinatumomab (given as a shot under the skin) and olverembatinib (a pill)—in 60 adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL). The goal is to see if this combo can control the disease safely. Pa…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Can a bispecific antibody wipe out residual leukemia cells in High-Risk CLL?
Disease control Not yet recruitingResearchers are testing whether adding epcoritamab can help high-risk chronic lymphocytic leukemia (CLL) patients who are already taking a BTK inhibitor clear remaining cancer cells. The trial enrolls 24 adults with CLL and specific risk factors such as a 17p deletion, TP53 mutat…
Phase 2 • Sponsor: University of California, Irvine • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Two-Drug combo targets tough Non-Hodgkin's lymphoma
Disease control Not yet recruitingResearchers are testing two experimental drugs, SCTB35 and SCTB41, in adults with B-cell non-Hodgkin's lymphoma that has returned or stopped responding to at least two prior treatments. Participants receive the drugs together, with or without chemotherapy, to find a safe dose and…
Phase 1/2 • Sponsor: Sinocelltech Ltd. • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Can a gentler dose of zanubrutinib keep CLL at bay in the very elderly?
Disease control Not yet recruitingThis phase II trial is testing whether a planned dose reduction of the targeted therapy zanubrutinib can maintain control of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) while reducing long-term side effects in patients aged 80 and older who have not yet…
Phase 2 • Sponsor: The Lymphoma Academic Research Organisation • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Can two immune boosters outsmart follicular lymphoma without chemo?
Disease control Not yet recruitingThis phase II trial is testing whether combining two lab-made antibodies, tafasitamab and rituximab, can help people with newly diagnosed follicular lymphoma achieve complete remission. Both antibodies are designed to help the immune system recognize and attack cancer cells. The …
Phase 2 • Sponsor: University of Washington • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Smartphone app and wearable sensor team up to catch infections early in cancer care
Disease control Not yet recruitingResearchers at Mayo Clinic are studying a remote monitoring program called SHIELD for cancer patients who are starting systemic therapy. Participants use a smartphone app to report symptoms and wear a small temperature sensor. The app and sensor send data to the medical record, w…
Sponsor: Mayo Clinic • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New complement inhibitor takes on established PNH drug in phase III trial
Disease control Not yet recruitingResearchers are testing an experimental drug called VSA012 against eculizumab in adults with paroxysmal nocturnal hemoglobinuria (PNH) who have not received complement inhibitor therapy. The trial enrolls about 70 participants and compares how well each treatment controls hemolys…
Phase 3 • Sponsor: Bisirna Therapeutics (Suzhou) Co., Ltd. • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Experimental cell therapy targets kidney disease
Disease control Not yet recruitingThis early-phase trial is testing a new cell therapy called GT719 for several immune-mediated kidney diseases, including IgA nephropathy and membranous nephropathy. The therapy uses specially engineered immune cells to target and potentially control the disease. The study will en…
Early phase 1 • Sponsor: Grit Biotechnology • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Can a new drug combo reach lymphoma hiding in the brain?
Disease control Not yet recruitingResearchers are testing whether adding pirtobrutinib to methotrexate and standard chemoimmunotherapy can help people with diffuse large B-cell lymphoma that has spread to the central nervous system. The trial enrolls about 24 people aged 14 to 80 whose lymphoma involves the brain…
Phase 2 • Sponsor: Pengpeng Xu • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Dual-Pronged CAR T-Cell therapy takes aim at Hard-to-Treat leukemia
Disease control Not yet recruitingThis phase 1 trial tests a new cell therapy called KITE-753 for adults with B-cell acute lymphoblastic leukemia (B-ALL) that has come back or not responded to standard treatments. KITE-753 is made from a patient's own immune cells, which are modified to recognize and attack leuke…
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Experimental drug F182112 tested against Hard-to-Treat blood disorder
Disease control Not yet recruitingResearchers are testing an experimental intravenous drug called F182112 in adults with autoimmune hemolytic anemia that has returned or resisted multiple treatments. The trial enrolls about 12 people and gives the drug at three increasing dose levels to check safety, tolerability…
Phase 1 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Off-the-Shelf immune cells take aim at Hard-to-Treat leukemia
Disease control Not yet recruitingThis early-phase trial is testing an experimental therapy called GT737 for adults with acute myeloid leukemia (AML) that has come back or not responded to standard treatment. GT737 uses specially engineered immune cells (iNKT cells) that are made in large batches and can be given…
Early phase 1 • Sponsor: Grit Biotechnology • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Cataract lens under the microscope: does it stay put?
Disease control Not yet recruitingResearchers are studying how stable the RayOne RAO800S intraocular lens is after cataract surgery. The lens replaces the eye's cloudy natural lens and has marks to help surgeons position it. Adults scheduled for cataract surgery in both eyes receive the lens as part of routine ca…
Sponsor: Rayner Intraocular Lenses Limited • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New hope for AML patients: experimental drug IPN60340 enters key trial
Disease control Not yet recruitingThis study tests whether adding the experimental drug IPN60340 to standard medicines (azacitidine and venetoclax) helps more people with newly diagnosed acute myeloid leukemia (AML) achieve complete remission. About 450 adults who cannot have intensive chemotherapy will take part…
Phase 2/3 • Sponsor: Ipsen • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Can a Three-Drug combo erase mantle cell lymphoma without chemotherapy?
Disease control Not yet recruitingResearchers are testing whether a combination of three drugs, zanubrutinib, obinutuzumab, and sonrotoclax (called BOSon), can effectively treat mantle cell lymphoma in people who have not had prior treatment and are not eligible for a stem cell transplant. The study will enroll a…
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Oral drug combo targets myeloma that escaped the bone marrow
Disease control Not yet recruitingResearchers are testing an experimental oral drug called HP-001 alongside dexamethasone in adults whose multiple myeloma has returned after treatment and has formed tumors outside the bone marrow. Participants take HP-001 capsules once daily for 10 days of each 28-day cycle, plus…
Phase 2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Can an old malaria drug make resistant leukemia vulnerable again?
Disease control Not yet recruitingResearchers are testing whether adding hydroxychloroquine to oral decitabine and venetoclax helps adults with acute myeloid leukemia (AML) that has relapsed or stopped responding to similar treatment. The study enrolls about 18 people with relapsed or refractory AML, or newly dia…
Phase 1 • Sponsor: Rutgers, The State University of New Jersey • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New Three-Drug cocktail aims to beat aggressive leukemia
Disease control Not yet recruitingThis study tests a new combination of three drugs—revumenib, azacitidine, and venetoclax—in people newly diagnosed with a specific, hard-to-treat leukemia called KMT2A-rearranged AML. The goal is to see if this cocktail can help more patients achieve remission with fewer side eff…
Phase 2 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Two pills, one goal: a Time-Limited oral combo takes aim at returning blood cancer
Disease control Not yet recruitingResearchers are testing whether a fixed course of two oral drugs, zanubrutinib and sonrotoclax, can shrink chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back after earlier treatment. The trial enrolls about 44 adults whose cancer progressed …
Phase 2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Can a Faster-Dosed antibody drug paired with lenalidomide help lymphoma that came back after CAR T-Cell therapy?
Disease control Not yet recruitingResearchers are testing a combination of two drugs, epcoritamab and lenalidomide, in adults whose large B-cell lymphoma has come back after CAR T-cell therapy. The trial enrolls about 55 people in France. Participants receive epcoritamab as a shot under the skin using a faster do…
Phase 2 • Sponsor: The Lymphoma Academic Research Organisation • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Can a Three-Drug combo shield stem cell transplant patients from a dangerous immune attack?
Disease control Not yet recruitingThis trial tests a combination of sirolimus, ruxolitinib, and mycophenolate mofetil to prevent acute graft-versus-host disease (aGVHD) in patients receiving a half-matched stem cell transplant. The study focuses on patients with blood cancers or severe aplastic anemia who cannot …
Phase 1/2 • Sponsor: Peking University People's Hospital • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New combo therapy aims to boost red blood cells in bone marrow disease
Disease control Not yet recruitingThis study tests whether adding epoetin alfa or emavusertib to luspatercept helps people with low-risk myelodysplastic syndrome (MDS) and anemia. MDS is a bone marrow disorder that leads to low blood counts. The goal is to see if these combinations improve red blood cell producti…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Can a targeted drug boost stem cell transplants for leukemia?
Disease control Not yet recruitingThis phase II trial tests whether adding venetoclax to standard chemotherapy and stem cell transplant, followed by venetoclax maintenance, helps adults with acute myeloid leukemia (AML) stay in remission longer. About 244 participants will receive either venetoclax or a placebo a…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New drug cocktail aims to wipe out Hard-to-Treat leukemia and MDS
Disease control Not yet recruitingThis phase 2 trial tests whether adding olutasidenib to standard treatments helps people with IDH1-mutated acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). For AML, the standard is a chemotherapy pill plus venetoclax; for higher-risk MDS, it's the chemotherapy pill…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New drug aims at CD123 to fight Hard-to-Treat blood cancers
Disease control Not yet recruitingResearchers are testing an experimental drug called ORM-1153 in adults whose acute myeloid leukemia (AML) or other blood cancer has returned or stopped responding to treatment. The drug targets CD123, a protein found on the surface of these cancer cells. Participants receive ORM-…
Phase 1 • Sponsor: Orum Therapeutics USA, Inc. • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New antibody JS203 takes on rituximab in Head-to-Head lymphoma trial
Disease control Not yet recruitingResearchers are testing whether an experimental antibody called JS203, added to gemcitabine and oxaliplatin chemotherapy, helps adults with diffuse large B-cell lymphoma (DLBCL) that has come back or stopped responding to treatment. The trial compares this combination against the…
Phase 3 • Sponsor: Shanghai Junshi Bioscience Co., Ltd. • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New drug combo aims to tailor myeloma treatment to each patient
Disease control Not yet recruitingThis Phase 3 trial is testing a personalized approach for people with newly diagnosed multiple myeloma who are eligible for a stem cell transplant. After initial treatment with a four-drug combination (isatuximab, iberdomide, bortezomib, and dexamethasone), the next steps—consoli…
Phase 3 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Can a weekly shot bring antibody levels to safety in untreated immune deficiency?
Disease control Not yet recruitingThis trial tests whether TAK-664, an antibody replacement given under the skin, can quickly raise and maintain protective IgG levels in people with primary immunodeficiency who have never received antibody therapy. Participants receive daily doses for 5 days, then a dose on day 8…
Phase 4 • Sponsor: Takeda • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Can engineered cells beat blood cancers that Won't quit?
Disease control Not yet recruitingThis early-phase trial tests an experimental cell therapy called iMagic Injection in adults with relapsed or refractory blood cancers, specifically B-cell non-Hodgkin lymphoma and multiple myeloma. Participants receive a single infusion of engineered immune cells designed to atta…
Early phase 1 • Sponsor: Suzhou Immunofoco Biotechnology Co., Ltd • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New hope for rare immune disorders: upadacitinib trial launches
Disease control Not yet recruitingThis study tests the drug upadacitinib (Rinvoq) in 30 people with rare genetic disorders that overactivate the JAK-STAT immune pathway. The trial has four phases over 12 months, including an open-label phase to find the best dose and a randomized withdrawal phase to compare the d…
Phase 1/2 • Sponsor: Lisa Satter • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Can a new injection tame the blood cell destruction of PNH?
Disease control Not yet recruitingThis Phase II trial tests an experimental drug called SGB-9768 in adults with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder where red blood cells break apart too early. The study gives the drug by injection under the skin and measures how well it lowers a marke…
Phase 2 • Sponsor: Suzhou Sanegene Bio Inc. • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New study tests minimally invasive heart valve repair to cut hospital stays
Disease control Not yet recruitingThis study tests whether a minimally invasive heart valve repair procedure (TEER) plus standard medication can reduce hospital readmissions over two years in people with moderate mitral regurgitation that worsens with exertion. About 300 participants will be randomly assigned to …
Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Can a tailored drug combo improve early response in chronic myeloid leukemia?
Disease control Not yet recruitingThis phase II trial tests asciminib as the first treatment for adults newly diagnosed with chronic myeloid leukemia in chronic phase. Patients with unfavorable risk factors also receive dasatinib starting four weeks later. The study measures how many patients achieve a major mole…
Phase 2 • Sponsor: Prof. Dr. med. Andreas Hochhaus • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
A diet tweak may boost platelets in a bleeding disorder
Disease control Not yet recruitingThis trial tests whether adding a selective Mediterranean diet to standard treatment can improve platelet counts and reduce bleeding in adults with immune thrombocytopenia (ITP), a condition where the immune system attacks platelets. Sixty adults aged 18 to 60 with low platelet c…
Sponsor: Assiut University • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New Immunotherapy-Chemo cocktail takes on tough lymphoma
Disease control Not yet recruitingThis early-phase trial tests the safety and best dose of glofitamab, an antibody that helps the immune system attack cancer, when given alongside standard chemotherapy (R-CHOP and R-DHAP) for people with untreated mantle cell lymphoma. Sixteen adults aged 18 to 75 with stage II b…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Can a menin-blocking drug outsmart stubborn leukemia?
Disease control Not yet recruitingThis trial is testing an experimental drug called S243249, which blocks a protein called menin, in people whose acute leukemia has come back or not responded to standard treatment. The study focuses on patients with specific genetic changes (KMT2A or NUP98 translocations, or NPM1…
Phase 1/2 • Sponsor: Servier • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Can a special diet before heart surgery cut the need for blood transfusions?
Disease control Not yet recruitingThis trial tests whether a nutrition program before elective open-heart surgery can reduce blood transfusions in patients with mild anemia. Participants receive a high-protein diet with iron and vitamin supplements, plus educational materials, for 8 to 12 weeks before their opera…
Phase 3 • Sponsor: National Institute of Cardiovascular Diseases, Pakistan • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New cocktail aims to tame myeloma without transplant
Disease control Not yet recruitingThis study tests a combination of four drugs (isatuximab, iberdomide, bortezomib, and dexamethasone) in 88 adults newly diagnosed with multiple myeloma who cannot or choose not to have a stem cell transplant. The goal is to find the safest dose and see how well the drugs control …
Phase 1/2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Could a Pharmacist's advice boost anemia treatment in pregnancy?
Disease control Not yet recruitingThis trial tests whether structured counseling from a pharmacist can help pregnant women with anemia stick to their treatment and raise their hemoglobin levels. Researchers will enroll 100 anemic pregnant women in Pakistan and split them into two groups: one receives routine care…
Sponsor: Hamdard University • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New stem cell filtering method could make transplants safer for kids
Disease control Not yet recruitingThis early-phase study tests a new way to do stem cell transplants for children and young adults with blood diseases. Doctors will take stem cells from a family member or closely matched unrelated donor, filter out certain immune cells using a special machine, and then give them …
Phase 1 • Sponsor: University of Wisconsin, Madison • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New drug cocktail aims to outsmart aggressive myeloma
Disease control Not yet recruitingThis phase 2 trial tests whether giving two bispecific antibodies (teclistamab and talquetamab) in sequence, along with other drugs, can improve survival in 50 people with high-risk multiple myeloma. Some participants may also receive a stem cell transplant if cancer cells remain…
Phase 2 • Sponsor: University of Arkansas • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Can a smart drug spare healthy cells while killing lymphoma?
Disease control Not yet recruitingThis trial is testing an experimental drug called FG-M131 in people with a type of blood cancer called peripheral T-cell lymphoma that has come back or not responded to prior treatment. FG-M131 is designed to target and destroy cancerous T cells that carry a marker called TRBC1, …
Phase 1/2 • Sponsor: FutureGen Biopharmaceutical (Beijing) Co., Ltd • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Gene therapy aims to help hemophilia a patients make their own clotting factor
Disease control Not yet recruitingThis early-stage trial tests a gene therapy for people with hemophilia A, a bleeding disorder. The treatment uses a modified virus to deliver a working gene into the patient's own stem cells, which are then infused back. The goal is to help the body produce clotting factor VIII, …
Phase 1 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New drug cocktail aims to replace chemo for lymphoma patients
Disease control Not yet recruitingThis phase 2 trial is testing a combination of three drugs (polatuzumab vedotin, glofitamab, and tafasitamab) as a first-line treatment for people with diffuse large B-cell lymphoma or high-grade B-cell lymphoma. The goal is to see if this chemo-free approach can shrink tumors an…
Phase 2 • Sponsor: Brown University • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Off-the-Shelf CAR t cells take on tough blood cancers
Disease control Not yet recruitingThis early-phase trial tests a new 'universal' CAR T cell therapy (4SCAR19U) for people with B cell cancers that have come back or not responded to treatment. The therapy uses donor-derived immune cells engineered to target CD19 on cancer cells. The study aims to check safety and…
Phase 1 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Can a targeted drug outsmart a rare blood cancer?
Disease control Not yet recruitingThis phase 2 trial tests whether teclistamab can treat Waldenstrom's macroglobulinemia, a rare blood cancer, in people whose disease has returned or not responded to prior therapy. Participants receive teclistamab as a subcutaneous injection for up to 9 cycles. Researchers measur…
Phase 2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
A snack bar that fights anemia? researchers put it to the test
Disease control Not yet recruitingThis trial tests whether a daily iron-rich snack bar can improve hemoglobin levels in adolescent girls with mild anemia. Researchers plan to enroll 100 girls aged 16 to 18, with half eating two bars each day for 12 weeks while the other half follows their usual diet. The bars are…
Sponsor: University of Veterinary and Animal Sciences, Lahore - Pakistan • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Can a withdrawn myeloma drug make a comeback with a gentler schedule?
Disease control Not yet recruitingThis study tests whether the drug belantamab mafodotin, given every 6 weeks alongside a steroid, can be safely used in community clinics for patients with relapsed or refractory multiple myeloma. The drug was previously removed from the market after a confirmatory study failed, b…
Phase 2 • Sponsor: Cristiana Costa Chase, DO • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Could a common blood thinner replace warfarin for LVAD patients?
Disease control Not yet recruitingThis study compares two blood thinners—apixaban (Eliquis) and warfarin (Coumadin)—in 460 people with advanced heart failure who have a HeartMate 3 heart pump. The goal is to see which drug better prevents strokes, pump clots, and serious bleeding. Participants must have had their…
Phase 3 • Sponsor: Columbia University • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Can a new drug combo boost remission in adult leukemia?
Disease control Not yet recruitingThis trial tests whether adding lishatoclax to standard chemotherapy, targeted drugs, or immunotherapies can improve remission rates in adults newly diagnosed with acute lymphoblastic leukemia (ALL). Researchers will enroll 30 patients across three subtypes: Philadelphia chromoso…
Sponsor: LanZhou University • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
New hope for myeloma patients: could ramantamig plus daratumumab outperform standard care?
Disease control Not yet recruitingThis phase 3 trial will compare a new treatment, ramantamig plus daratumumab, against two standard drug combinations for people newly diagnosed with multiple myeloma who are not eligible for a stem cell transplant. The study aims to see if the new combo can keep the cancer from p…
Phase 3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Protein and saline mist may cut bleeding risk after tonsil removal
Disease control Not yet recruitingThis trial tests whether giving patients extra protein and saline mist after tonsillectomy helps them heal faster and avoid complications. Tonsil removal is common in children and adults, but it often causes pain, trouble swallowing, and a risk of bleeding. The researchers will c…
Phase 3 • Sponsor: Hospital Felicio Rocho • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Can a Four-Drug combo tame Ultra-High-Risk myeloma?
Disease control Not yet recruitingThis phase 2 trial tests whether adding elranatamab to a standard three-drug regimen can improve outcomes for people newly diagnosed with ultra-high-risk multiple myeloma. Researchers will give 15 participants elranatamab, isatuximab, bortezomib, and lenalidomide, and measure how…
Phase 2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Can engineered immune cells calm autoimmune blood disorders?
Disease control Not yet recruitingThis phase 1 trial tests a one-time infusion of AZD0120, a CAR-T cell therapy that targets CD19 and BCMA, in people with relapsed or refractory immune thrombocytopenia (ITP) or warm autoimmune hemolytic anemia (wAIHA). Participants receive a short course of bendamustine before th…
Phase 1 • Sponsor: Saurabh Dahiya • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Can an RNA 'Message' reprogram the immune system to stop autoimmune blood disorders?
Disease control Not yet recruitingThis early-stage trial is testing an experimental therapy called RXIM002 in adults with relapsed or refractory autoimmune cytopenias, including immune thrombocytopenia (ITP). The therapy uses a special RNA molecule to instruct the body to produce CAR T cells that target and poten…
Phase 1 • Sponsor: RiboX Therapeutics Ltd. • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Can a Two-Drug chemo combo outsmart resistant tumors?
Disease control Not yet recruitingThis early-stage trial is testing whether combining two chemotherapy drugs—liposomal irinotecan and cisplatin—can safely shrink or control advanced solid tumors that have not responded to standard treatments. The study will enroll about 44 adults aged 20 to 85 with various types …
Phase 1 • Sponsor: National Health Research Institutes, Taiwan • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
New drug combo targets Tough-to-Treat myeloma
Disease control Not yet recruitingThis phase 2 trial is testing a new drug called CM336, given alongside standard therapy, for people with high-risk multiple myeloma. The study will include 46 adults aged 18 to 75. The main goal is to see if the combination can reduce cancer cells to very low levels (MRD negativi…
Phase 2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Can cancer care include heart checks? a pilot study puts two models to the test
Disease control Not yet recruitingThis pilot study explores whether a structured heart-health assessment can be done successfully and on time for adults with multiple myeloma who are starting a new line of treatment. Participants will be assigned by chance to receive the assessment either from a clinician embedde…
Sponsor: University of Vermont Medical Center • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
Can a new drug take on multiple tough cancers?
Disease control Not yet recruitingThis early-stage trial tests an investigational drug called CBX-663 in adults with certain advanced cancers that have not responded to standard treatment or have returned. The study includes people with blood cancers (like AML, MDS, or CMML), advanced solid tumors, or a type of b…
Phase 1 • Sponsor: Crossbow Therapeutics, Inc. • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
One iron shot vs. many: which fixes Post-Surgery anemia faster?
Disease control Not yet recruitingThis trial tests whether a single dose of ferric carboxymaltose can treat iron-deficiency anemia after stomach cancer surgery as effectively as multiple doses of iron sucrose. About 160 adults who had curative stomach cancer surgery and developed anemia will be randomly assigned …
Phase 4 • Sponsor: Zhaojian Niu,MD • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
A pill after transplant: new hope to stop t-cell cancer relapse
Disease control Not yet recruitingThis trial tests whether taking chidamide, an oral drug, after a stem cell transplant can lower the chance of the cancer coming back in people with high-risk T-cell acute lymphoblastic leukemia or lymphoma. Participants are randomly assigned to receive chidamide for up to 24 mont…
Phase 3 • Sponsor: First Affiliated Hospital of Zhejiang University • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Could simple guidelines cut ICU anemia deaths?
Disease control Not yet recruitingThis study tests whether providing hospitals with a structured program to follow anemia prevention and management guidelines can lower death rates in intensive care unit (ICU) patients. The trial will involve about 5,760 adults who stay in the ICU for at least two days and have o…
Sponsor: University Hospital, Angers • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
Can a common drug boost Chemo's power against Hard-to-Treat leukemia?
Disease control Not yet recruitingThis trial is testing whether adding hydroxyurea to a standard chemotherapy combination can improve outcomes for adults with acute myeloid leukemia (AML) that has returned or not responded to treatment. The study is conducted in two parts: first to find the safest dose of hydroxy…
Phase 1/2 • Sponsor: Christer C Nilsson • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Can a Two-Drug immune attack shrink Hard-to-Treat pancreatic tumors?
Disease control Not yet recruitingThis phase 2 trial is testing whether combining two immunotherapy drugs—vilastobart and retifanlimab—can shrink tumors in people with metastatic pancreatic cancer that has a BRCA1, BRCA2, or PALB2 gene mutation. Participants receive both drugs by IV infusion over several months. …
Phase 2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Can an immune booster outsmart brain lymphoma?
Disease control Not yet recruitingThis trial is testing whether adding an immunotherapy drug called penpulimab to a standard chemotherapy regimen can help people with primary central nervous system lymphoma, a rare type of brain cancer. Participants, who have not yet received treatment, are randomly assigned to r…
Sponsor: WEI XU • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Can a Two-Drug combo outsmart resistant myeloma?
Disease control Not yet recruitingThis phase II trial is testing whether combining teclistamab, an antibody that helps immune cells attack myeloma cells, with pomalidomide, a drug that slows cancer growth, can control multiple myeloma in people whose disease has returned or stopped responding after 1-3 prior trea…
Phase 2 • Sponsor: Odense University Hospital • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New hope for young adults with CML: asciminib under Real-World scrutiny
Disease control Not yet recruitingThis study looks at how well the drug asciminib works and how safe it is for young adults with chronic myeloid leukemia (CML) in the Gulf region. Researchers will collect information from medical records of about 80 people aged 18 and older who have taken asciminib. The main goal…
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can a Triple-Drug combo outsmart resistant leukemia?
Disease control Not yet recruitingThis trial tests whether adding gilteritinib to the standard drugs azacitidine and venetoclax can help adults with a type of acute myeloid leukemia (AML) that has returned or stopped responding to prior treatment. Participants receive the three-drug combination in repeated 28-day…
Phase 2 • Sponsor: Florian Kuchenbauer • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can antibody infusions outperform antibiotics in shielding CAR-T patients from infections?
Disease control Not yet recruitingThis phase III trial is testing whether regular antibody infusions (immunoglobulin replacement therapy) can prevent infections better than standard antibiotic prophylaxis in people who have received CAR-T cell therapy for B-cell acute lymphoblastic leukemia or B-cell lymphoma. CA…
Phase 3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can a new daily pill shrink the spleen and ease myelofibrosis symptoms?
Disease control Not yet recruitingThis phase 2 trial is testing whether an oral drug called flonoltinib maleate can help adults with myelofibrosis, a rare bone marrow disorder that often causes an enlarged spleen and severe symptoms. The study compares three different daily doses (50 mg, 75 mg, and 100 mg) to see…
Phase 2 • Sponsor: Chengdu Zenitar Biomedical Technology Co., Ltd • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can gene therapy free sickle cell patients from painful crises?
Disease control Not yet recruitingThis trial compares a new gene therapy to standard care in people aged 12 to 35 with severe sickle cell disease. The gene therapy uses a patient's own blood stem cells, modified to produce a therapeutic form of hemoglobin and reduce the sickling hemoglobin. The study measures how…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
A new hope for MDS patients: could this drug cut blood transfusions?
Disease control Not yet recruitingThis study looks at whether luspatercept, a drug given as first-line treatment, can help adults with low-risk myelodysplastic neoplasms (MDS) who need regular red blood cell transfusions. Researchers will follow about 190 participants for up to 2 years to see how often they achie…
Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Can a Dual-Targeting antibody stop amyloid buildup in its tracks?
Disease control Not yet recruitingThis phase 2 trial is testing an investigational drug called QLS4131 in people newly diagnosed with AL amyloidosis, a condition where abnormal proteins build up in organs and cause damage. QLS4131 is a trispecific antibody designed to target and eliminate the plasma cells produci…
Phase 2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Can a targeted drug shrink Hard-to-Treat thymic tumors?
Disease control Not yet recruitingThis phase II trial is testing whether an experimental drug called sacituzumab tirumotecan (Sac-TMT) can shrink tumors in people with thymic carcinoma that cannot be surgically removed and has already been treated with platinum-based chemotherapy. Participants receive the drug in…
Phase 2 • Sponsor: National Cancer Center, Japan • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Can a lower dose of a myeloma drug keep the disease in check with fewer side effects?
Disease control Not yet recruitingThis trial asks whether a reduced dose of belantamab mafodotin, combined with pomalidomide and dexamethasone, can control relapsed or refractory multiple myeloma as effectively as the standard dose while causing fewer side effects. Adults with this blood cancer who have had at le…
Phase 2 • Sponsor: Polish Myeloma Consortium • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Ready-Made immune cells take on blood cancers in early trial
Disease control Not yet recruitingThis early-phase study tests a new cell therapy called ALA-101 for people with CD19+ non-Hodgkin lymphoma or leukemia. The therapy uses donor immune cells that are specially designed to find and attack cancer cells. The main goals are to check safety and find the best dose, with …
Phase 1 • Sponsor: Arovella Therapeutics Ltd • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Can a targeted drug beat radiation for early-stage lymphoma?
Disease control Not yet recruitingThis phase 3 trial compares the experimental drug surovatamig with standard involved-site radiotherapy (with or without rituximab) in people with limited-stage follicular lymphoma. The goal is to see if surovatamig can produce deeper, longer-lasting responses and reduce the chanc…
Phase 3 • Sponsor: Australasian Leukaemia and Lymphoma Group • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
CLL patients may get a break from daily pills
Disease control Not yet recruitingThis study looks at whether people with chronic lymphocytic leukemia (CLL) who have been in remission for at least two years can safely stop taking their BTK inhibitor medication. The goal is to see how long they stay cancer-free without treatment, and whether stopping improves t…
Phase 2 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Can a simple injection replace an IV for this myeloma drug?
Disease control Not yet recruitingThis trial is testing whether belantamab, a drug used for multiple myeloma, can be given as a quick injection under the skin instead of a slow drip into a vein. About 22 adults with multiple myeloma who are already on standard maintenance therapy will receive both forms in a cros…
Phase 1 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Can a dual immunotherapy erase hidden myeloma cells?
Disease control Not yet recruitingThis phase 3 trial tests whether combining two immunotherapies, teclistamab and talquetamab, can eliminate residual cancer cells in multiple myeloma patients who have undergone a stem cell transplant. Participants with detectable minimal residual disease (MRD) are randomly assign…
Phase 3 • Sponsor: Polish Myeloma Consortium • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Parent-Child workouts may boost activity in kids with leukemia
Disease control Not yet recruitingThis trial tests whether a parent-child physical activity program can increase exercise levels in children aged 9–18 with leukemia who are on maintenance therapy. Children and parents attend weekly exercise sessions together for three months. The study compares this approach to c…
Sponsor: The Hong Kong Polytechnic University • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Can a Three-Drug combo outsmart High-Risk CLL?
Disease control Not yet recruitingThis phase 2 trial is testing whether adding a new immune-boosting drug, epcoritamab, to two existing targeted therapies (ibrutinib and venetoclax) can improve outcomes for people with untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have TP53 …
Phase 2 • Sponsor: The Lymphoma Academic Research Organisation • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Can Real-Time MRI make radiation safer for Ultra-Central lung tumors?
Disease control Not yet recruitingThis trial tests whether MRI-guided stereotactic body radiotherapy (SBRT) can safely treat ultra-central lung tumors—growths located near the windpipe and major airways. Using an MR-LINAC machine, doctors can adjust the radiation beam in real time as the patient breathes, potenti…
Sponsor: Centre Oscar Lambret • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Personalizing leukemia care for seniors: a fitness-based treatment strategy put to the test
Disease control Not yet recruitingThis phase 2 trial tests whether using a comprehensive geriatric assessment to guide treatment selection can reduce side effects and improve outcomes in adults aged 60 and older with newly diagnosed acute myeloid leukemia. Participants are classified as fit, vulnerable, or frail,…
Phase 2 • Sponsor: University of Rochester • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Can a menin inhibitor tame myelofibrosis when standard drugs fall short?
Disease control Not yet recruitingThis trial investigates whether revumenib, a menin inhibitor, can safely and effectively treat myelofibrosis, a type of bone marrow cancer. The study first tests revumenib alone in patients who have already tried a JAK inhibitor, then tests it in combination with a JAK inhibitor.…
Phase 1/2 • Sponsor: John Mascarenhas • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Can a targeted pill tame a rare immune disease?
Disease control Not yet recruitingThis phase 2 trial is testing whether the experimental drug luvometinib, taken alone or with the chemotherapy drug cytarabine, can control Langerhans cell histiocytosis—a rare disease where immune cells build up and damage tissues. People aged 10 and older who need systemic treat…
Phase 2 • Sponsor: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
Can a cancer drug reboot the immune system in chronic fatigue syndrome?
Disease control Not yet recruitingThis trial tests whether inebilizumab, an antibody that wipes out certain immune cells called B cells, can improve physical function in adults with ME/CFS that started after an infection. Participants receive three infusions over six months, and the study measures changes in mobi…
Phase 2 • Sponsor: Charite University, Berlin, Germany • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Can a burst of radiation make CAR t-cells fight cancer harder?
Disease control Not yet recruitingThis trial tests whether adding a small dose of total body radiation to standard CAR T-cell therapy can help the immune cells grow stronger and last longer in the body. It enrolls adults with relapsed or hard-to-treat diffuse large B-cell lymphoma or multiple myeloma who are alre…
Phase 1 • Sponsor: Weill Medical College of Cornell University • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
TikTok meets oncology: can influencer videos boost chemo adherence in teens?
Disease control Not yet recruitingThis trial tests whether a social media campaign, co-created with young adult cancer survivors who are also online influencers, can improve how consistently adolescents and young adults (ages 15–25) with acute lymphoblastic leukemia take their daily oral chemotherapy. Participant…
Sponsor: Northwestern University • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Experimental drug targets bone marrow failure
Disease control Not yet recruitingThis study tests an experimental drug called dibotatug (DR-01) in adults with bone marrow failure syndromes, including severe aplastic anemia. The goal is to see if the drug is safe and can improve blood cell counts. Participants receive dibotatug by IV infusion, and researchers …
Phase 1/2 • Sponsor: Dren Bio • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Simple breathing device may speed recovery from a deadly sickle cell complication
Disease control Not yet recruitingThis trial investigates whether continuous positive airway pressure (CPAP) can help adults with sickle cell disease recover faster from acute chest syndrome, a serious lung complication. Participants who need extra oxygen are randomly assigned to receive either standard oxygen al…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Could a spring-powered injector make cancer drug delivery smoother for patients and nurses?
Disease control Not yet recruitingThis trial tests whether a mechanical, spring-driven device called FreedomEDGE® can safely and effectively deliver daratumumab, a standard treatment for multiple myeloma and amyloidosis. Currently, nurses give these injections by hand, which can be physically demanding. About 100…
Sponsor: Hospices Civils de Lyon • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
New drug combo aims to outsmart lymphoma resistance
Disease control Not yet recruitingThis phase II trial tests whether adding lisaftoclax to brentuximab vedotin improves outcomes for people with CD30-positive cutaneous T-cell lymphoma, including mycosis fungoides and primary cutaneous anaplastic large cell lymphoma. About 46 participants are randomly assigned to …
Phase 2 • Sponsor: Peking University First Hospital • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Can a One-Two drug punch beat back Hard-to-Treat myeloma?
Disease control Not yet recruitingThis early-phase trial is testing whether combining two targeted drugs—talquetamab and belantamab mafodotin—can safely control multiple myeloma that has returned or stopped responding to prior treatments. The study enrolls adults with myeloma who have already tried at least one p…
Phase 1 • Sponsor: Montefiore Medical Center • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
New 'WARNING Pack' aims to protect quality of life in older cancer patients
Disease control Not yet recruitingThis trial tests a care package called the 'WARNING Pack' for people aged 75 and older with cancer. The pack helps doctors spot early signs of age-related problems and provides a guide for managing them. The goal is to prevent a decline in quality of life and reduce the risk of g…
Sponsor: Poitiers University Hospital • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
AI takes on lymphoma: personalized drug cocktail aims to outsmart cancer in older patients
Disease control Not yet recruitingThis study tests whether an artificial intelligence (AI) system can help choose the best combination of drugs for older patients newly diagnosed with large B-cell lymphoma. Participants are first treated with a standard two-drug regimen (ZR2), then those at intermediate or high r…
Phase 2 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
New combo therapy aims to boost remission in Hard-to-Treat lymphoma
Disease control Not yet recruitingThis phase 2 trial tests whether a combination of the targeted drug glofitamab with chemotherapy (gemcitabine and oxaliplatin) can improve the effectiveness of a CAR-T cell therapy called lisocabtagene maraleucel in people with relapsed or refractory aggressive B-cell lymphomas. …
Phase 2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New clot-sucking device tested in real-world vein clot treatment
Disease control Not yet recruitingThis study tracks how well the FLOWRUNNER Aspiration System removes symptomatic blood clots from veins in the arms or legs during routine care. About 218 adults with deep-vein clots will be followed to see if the device safely restores blood flow and reduces clot-related disabili…
Sponsor: FlowPhysix, Inc. • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Fewer radiation sessions may be just as effective for thymic tumors after surgery
Disease control Not yet recruitingThis clinical trial is testing a shorter, more intense course of radiation therapy (called hypofractionated radiotherapy) for people who have had surgery for thymic epithelial tumors, including thymoma and thymic carcinoma. The goal is to see if this approach can keep the tumor f…
Sponsor: National Taiwan University Hospital • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Genetic blueprint guides new lymphoma cocktail
Disease control Not yet recruitingThis trial tests whether adding targeted drugs (azacitidine or decitabine plus selinexor) to standard chemotherapy improves outcomes for people newly diagnosed with peripheral T-cell lymphoma. Participants are assigned treatment based on their tumor's genetic profile. The study f…
Phase 1/2 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Cuff-Limited exercise may boost blood health in anemic young women
Disease control Not yet recruitingThis study investigates whether combining aerobic exercise with blood flow restriction—using a pressure cuff on the thigh—can improve key blood markers in young women with iron deficiency anemia. Fifty participants aged 19-25 with mild to moderate anemia will walk on a treadmill …
Sponsor: Cairo University • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
AR goggles could help surgeons spot cancer cells left behind during breast cancer surgery
Disease control Not yet recruitingThis trial tests whether special augmented-reality goggles can help surgeons find lymph nodes that may be missed during breast cancer surgery. The goggles show a fluorescent dye that collects in lymph nodes, allowing the surgeon to re-examine the area after the planned removal is…
Sponsor: Ss. Cyril and Methodius University of Skopje • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Single-Dose gene therapy aims to reprogram immune cells against tough leukemia
Disease control Not yet recruitingThis early-phase trial tests a single injection of PID23, a gene therapy that instructs a patient's own immune cells to attack leukemia cells. It targets three markers (CD19, BCMA, and CD70) on cancer cells. The study enrolls up to 18 people aged 3 to 75 with relapsed or refracto…
Early phase 1 • Sponsor: Zhujiang Hospital • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Could a safer start to a key CLL drug be possible? new study reexamines the risk
Disease control Not yet recruitingThis study looks at people with chronic lymphocytic leukemia (CLL) who are about to start treatment with venetoclax, a targeted therapy. Doctors want to see if starting with other drugs first lowers the risk of tumor lysis syndrome, a dangerous side effect where cancer cells brea…
Sponsor: Private Hospital of Confluent, France • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Could a single iron infusion ease heart failure in seniors?
Disease control Not yet recruitingThis study tests whether a single intravenous dose of iron (ferric derisomaltose) can improve symptoms, reduce hospitalizations, and boost quality of life in adults aged 65 and older who have heart failure with preserved ejection fraction and iron deficiency. Participants receive…
Phase 4 • Sponsor: Duke University • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Gene-Guided Chemo-Free strategy targets AL amyloidosis
Disease control Not yet recruitingThis study tests two chemotherapy-free treatments for people newly diagnosed with AL amyloidosis, a rare blood disorder. The choice of treatment depends on whether the patient has a specific genetic change called t(11;14). Those with t(11;14) receive a daily pill called sonrotocl…
Phase 1/2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
New pill targets immune signals in rare lymphomas
Disease control Not yet recruitingThis pilot study tests an oral drug called golidocitinib in people with two rare blood cancers: mycosis fungoides/Sézary syndrome (a type of skin lymphoma) and T-cell large granular lymphocytic leukemia. The drug blocks a protein called JAK1, which is involved in cancer cell grow…
Phase 2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Two-Drug sequence aims to clear CLL cells and let patients stop treatment
Disease control Not yet recruitingThis phase 2 trial tests a treatment plan for people with newly diagnosed chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Participants first take zanubrutinib alone for 12 cycles, then add sonrotoclax for another 12 cycles. The goal is to see if this seque…
Phase 2 • Sponsor: Yi Shuhua • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Herbal mix and cancer drug join forces to fight fluid in lungs
Disease control Not yet recruitingThis study tests whether adding a Chinese herbal formula (Xuanyin Ning) to a standard cancer drug (bevacizumab) can better control malignant pleural effusion—fluid buildup in the chest caused by advanced lung cancer. About 308 participants will receive either the herbal formula o…
Sponsor: Shanghai Chest Hospital • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Smarter transfusions: tailoring blood use after heart surgery
Disease control Not yet recruitingThis study compares two ways of deciding when heart surgery patients need a blood transfusion in the ICU. One uses a fixed blood count threshold, while the other also considers each patient's oxygen and lactate levels. The goal is to see if the personalized approach is as safe an…
Sponsor: Yan Mia Min • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Could a 30-Day habit shift help blood cancer patients regain control?
Disease control Not yet recruitingThis study tests a self-management program called Take5Care+ for adults recently diagnosed with slow-growing blood cancers. Participants choose a healthy habit—like better nutrition or more physical activity—and commit to it for 30 days. The goal is to see if this simple approach…
Sponsor: Jitka Vseteckova • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Engineered donor cells aim to shield transplant patients from dangerous viruses
Disease control Not yet recruitingThis trial tests whether giving patients a special type of donor immune cell, called CD45RA-depleted DLI, can prevent serious viral infections after a stem cell transplant. The study includes 30 high-risk patients who have received a transplant for blood cancer. Researchers will …
Phase 1 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New Antibody-Azacitidine combo aims to boost remission in High-Risk blood cancer
Disease control Not yet recruitingThis phase 2 trial tests whether adding bexmarilimab, an antibody that targets Clever-1, to standard azacitidine chemotherapy improves outcomes for adults with newly diagnosed higher-risk myelodysplastic syndromes (HR-MDS). Participants are randomly assigned to receive one of two…
Phase 2 • Sponsor: Faron Pharmaceuticals Ltd • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Could a simple antibiotic keep blood cancer patients out of the hospital?
Disease control Not yet recruitingThis study tests whether taking a daily antibiotic (levofloxacin) can safely reduce infections in people with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) who are receiving chemotherapy as outpatients. The trial will randomly assign 75 participants to either lev…
Phase 2 • Sponsor: University of Manitoba • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New drug cocktail aims to deepen remission in multiple myeloma patients
Disease control Not yet recruitingThis Phase 3 trial tests whether adding the drug Teclistamab to a standard treatment regimen (Daratumumab, Lenalidomide, Bortezomib, Dexamethasone) improves outcomes for newly diagnosed multiple myeloma patients eligible for stem cell transplant. About 399 adults aged 18-70 will …
Phase 3 • Sponsor: University of Heidelberg Medical Center • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New study aims to stop blood cancer relapse after transplant
Disease control Not yet recruitingThis study tests whether giving personalized maintenance therapy after a stem cell transplant can prevent cancer from coming back in people with certain blood cancers. About 450 adults with myeloid cancers who have signs of disease before transplant will be assigned to treatment …
Phase 2 • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug cocktail aims to tackle tough lymphoma
Disease control Not yet recruitingThis study tests a combination of two drugs, glofitamab and selinexor, in 30 adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who have already tried at least two other treatments. The goal is to see how many patients achieve a complete response (cancer dis…
Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Zapping kidney nerves: a Needle-Free hope for high blood pressure?
Disease control Not yet recruitingThis pilot study tests a new device that uses radiofrequency energy to calm overactive kidney nerves, which can drive high blood pressure. Twenty adults with untreated mild hypertension will either get the real procedure or a sham (fake) one. The main goal is to see if the real t…
Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New hope for kids with ITP: drug combo aims to control bleeding
Disease control Not yet recruitingThis phase 2 trial tests whether adding ianalumab to eltrombopag helps children aged 5 to 17 with primary immune thrombocytopenia (ITP) who didn't improve after steroids. The goal is to see if the combination can raise platelet counts and prevent bleeding. About 36 children will …
Phase 2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New dosing strategy aims to reduce eye side effects in myeloma treatment
Disease control Not yet recruitingThis phase 2 trial is testing whether different dosing schedules of belantamab mafodotin, when combined with bortezomib and dexamethasone, can reduce the risk of serious eye problems while still controlling multiple myeloma. About 150 adults with relapsed or refractory multiple m…
Phase 2 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New cream targets skin lymphoma without steroids
Disease control Not yet recruitingThis study tests a cream called benvitimod (tapinarof) for people with cutaneous T-cell lymphoma, a rare skin cancer that causes red patches and itching. The cream is non-steroidal and works by targeting a specific receptor in skin cells. About 35 adults with the disease will app…
Phase 2 • Sponsor: Peking University First Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Smart blood pressure cuffs could protect cancer patients from heart risks
Disease control Not yet recruitingThis pilot study tests whether a connected blood pressure monitor, supervised daily by a healthcare assistant, helps patients with blood cancers like CLL or lymphoma stick to home monitoring. The goal is to catch and manage high blood pressure early, a common side effect of BTK i…
Sponsor: Centre Hospitalier de la côte Basque • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Can a maintenance drug keep lymphoma at bay? new trial aims to find out.
Disease control Not yet recruitingThis phase 2 trial tests whether giving rituximab maintenance therapy after initial treatment with rituximab and lenalidomide (R2) can improve outcomes for people with untreated marginal zone lymphoma. About 144 patients who respond to R2 will be randomly assigned to receive ritu…
Phase 2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug aims to lock in remission for rare lymphoma
Disease control Not yet recruitingThis study tests whether the drug elranatamab can help keep plasmablastic lymphoma, a rare and aggressive blood cancer, from returning after initial chemotherapy. About 17 adults with or without HIV who have already responded to first treatment will receive elranatamab injections…
Phase 2/3 • Sponsor: University of Illinois at Chicago • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug aims to keep platelets up during breast cancer chemo
Disease control Not yet recruitingThis phase 2 study tests whether the drug hetrombopag can prevent dangerously low platelet counts caused by chemotherapy in breast cancer patients at high risk. About 126 participants will be split into three groups: one getting no preventive drug, one taking hetrombopag continuo…
Phase 2 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug cocktail aims to tackle myeloma that resists CAR-T therapy
Disease control Not yet recruitingThis study tests a combination of two drugs, belantamab mafodotin and mezigdomide, in 44 adults with multiple myeloma whose cancer returned after treatment with CAR-T cells or bispecific antibodies. The goal is to see if the combo can control the cancer longer. The trial starts w…
Phase 1/2 • Sponsor: Centre Hospitalier Universitaire de Saint Etienne • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Could LVAD patients ditch aspirin? new trial aims to find out
Disease control Not yet recruitingThis study tests whether patients with a heart pump (LVAD) can safely stop taking aspirin while continuing warfarin. The goal is to reduce bleeding problems without increasing dangerous clots. About 370 participants will be randomly assigned to receive either aspirin or a placebo…
Phase 4 • Sponsor: China National Center for Cardiovascular Diseases • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Blood clot risk in rare disease: could a higher dose of clopidogrel offer better protection?
Disease control Not yet recruitingThis study looks at whether a higher dose of the blood thinner clopidogrel works better for people with essential thrombocythemia (ET), a rare blood disorder that raises the risk of dangerous blood clots. The standard dose may not work well for many ET patients, so researchers wi…
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Could cord blood transfusions protect fragile preemies?
Disease control Not yet recruitingThis study tests whether using cord blood, rich in fetal hemoglobin, for transfusions in preterm infants can reduce serious complications like blindness, lung disease, and gut problems. Researchers will compare outcomes in 200 very low birth weight babies who receive either cord …
Sponsor: University of Parma • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Real-World check: Asciminib's performance in Tough-to-Treat CML
Disease control Not yet recruitingThis study will follow about 98 adults with chronic myeloid leukemia who are taking asciminib after other treatments have stopped working. Researchers want to see how many patients achieve a major molecular response (a key sign of disease control) after two years. The goal is to …
Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New combo therapy aims to outsmart leukemia with less poison
Disease control Not yet recruitingThis phase 2 trial is testing a new way to treat adults newly diagnosed with a specific type of acute lymphoblastic leukemia (Ph-negative B-ALL). Instead of standard high-dose chemotherapy, patients receive a mix of low-dose chemo plus several targeted drugs (inotuzumab ozogamici…
Phase 2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Radiation and immunotherapy team up against hard-to-treat lymphoma
Disease control Not yet recruitingThis study tests whether giving radiation therapy before the immunotherapy drugs obinutuzumab and glofitamab can improve outcomes for people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). About 40 adults who have already tried at least two prior treatments wil…
Phase 2 • Sponsor: Olivia Newton-John Cancer Research Institute • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New combo aims to fix transfusion failure in blood cancer patients
Disease control Not yet recruitingThis phase 3 trial tests whether acalabrutinib (a BTK inhibitor) alone or with bortezomib can lower harmful HLA antibodies that cause platelet transfusions to fail in blood cancer patients. About 42 adults with platelet transfusion refractoriness and high antibody levels will be …
Phase 3 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New CLL combo aims for Long-Term remission without lifelong pills
Disease control Not yet recruitingThis phase II trial tests a new drug called pirtobrutinib combined with a short course of chemotherapy in 82 fit patients with untreated CLL. The goal is to achieve deep remission with undetectable cancer cells in the blood at 24 months. The treatment lasts only 15 months, aiming…
Phase 2 • Sponsor: French Innovative Leukemia Organisation • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New IVIG aims to slash infection risk for immune-deficient patients
Disease control Not yet recruitingThis study tests a new medicine called Boya IVIG in 50 people with primary immunodeficiency (CVID or XLA), a condition where the body can't fight infections well. Participants get the drug every 21 or 28 days for a year to see if it keeps serious bacterial infections below one pe…
Phase 3 • Sponsor: Azidus Brasil • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Experimental CAR-T therapy targets tough childhood blood cancers
Disease control Not yet recruitingThis early-phase trial is testing a new treatment called PA3-17 injection for children and teens aged 3 to 18 with T-cell leukemia or lymphoma that has not responded to standard therapy or has come back. The treatment uses the patient's own immune cells, modified to recognize and…
Phase 1 • Sponsor: PersonGen BioTherapeutics (Suzhou) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New pill takes on tough blood cancers in first human trial
Disease control Not yet recruitingThis early-stage study tests a new tablet, FXS0683, in 228 adults with blood cancers like lymphoma or leukemia that returned or didn't respond to standard therapy. The main goals are to check safety, find the best dose, and see if the drug shrinks tumors. Participants will be clo…
Phase 1 • Sponsor: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Could vitamin c tame anemia? early trial tests high doses in rare blood disorders
Disease control Not yet recruitingThis early-stage study tests whether high-dose Vitamin C is safe for people with two rare inherited blood disorders—Pyruvate Kinase Deficiency (PKD) and a form of G6PD deficiency. Both conditions cause red blood cells to break down too quickly, leading to anemia. The study will e…
Phase 1 • Sponsor: University of Utah • Aim: Disease control
Last updated Jun 27, 2026 12:39 UTC
-
AI helps target stomach cancer with less harm to healthy organs
Disease control Not yet recruitingThis study tests a new way to deliver radiation for gastric MALT lymphoma. Using AI, the treatment adapts each session to better protect nearby organs. About 25 adults with early-stage disease will take part. The goal is to see if this approach is safe and effective.
Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Immune cell therapy trial offers new hope for young hodgkin lymphoma patients
Disease control Not yet recruitingThis early-stage trial tests a new treatment for children, adolescents, and young adults with a certain type of Hodgkin lymphoma that has come back after initial therapy. The treatment uses the patient's own immune cells, which are modified in a lab to recognize and attack cancer…
Phase 1 • Sponsor: New York Medical College • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
AI takes on lymphoma: personalized treatment strategy under trial
Disease control Not yet recruitingThis study compares an AI-driven treatment strategy to standard therapy (Pola-R-CHP) for people with previously untreated large B-cell lymphoma. About 178 participants will be grouped by risk using an AI model, and those at intermediate or high risk will receive either a personal…
Phase 2 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New 5-Drug cocktail aims to tackle High-Risk myeloma
Disease control Not yet recruitingThis study tests a new five-drug combination for people newly diagnosed with a high-risk form of multiple myeloma. The drugs include etentamig, isatuximab, bortezomib, lenalidomide, and dexamethasone. The trial will enroll 220 participants and first check safety, then see if the …
Phase 1/2 • Sponsor: Universitätsklinikum Hamburg-Eppendorf • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New hope for older AML patients: gentler transplant approach aims to boost survival with less toxicity
Disease control Not yet recruitingThis study tests a reduced-intensity chemotherapy combination (fludarabine and treosulfan) before a half-matched stem cell transplant in 77 older or frail adults with AML. The goal is to see if this gentler regimen can control the leukemia long-term while being safe enough for pa…
Phase 2 • Sponsor: Institut Paoli-Calmettes • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Which Pre-CAR-T chemo is safer? new trial aims to find out
Disease control Not yet recruitingThis trial tests whether bendamustine causes fewer severe side effects than the standard fludarabine/cyclophosphamide combination when given before CAR-T cell therapy for B-cell lymphoma. About 92 people will be randomly assigned to one of the two chemotherapy regimens. The main …
Phase 2 • Sponsor: Swiss Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New drug cocktail aims to shrink untreated lymphoma tumors
Disease control Not yet recruitingThis study tests a combination of three drugs (orelabrutinib, tafasitamab, and lenalidomide) as a first treatment for people with follicular lymphoma, a slow-growing blood cancer. The goal is to see how well the drugs shrink tumors and how safe they are. About 27 newly diagnosed …
Phase 2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Could early antibiotic stop be safe for kids with cancer?
Disease control Not yet recruitingThis trial looks at whether children with cancer who develop a fever and low white blood cells can safely stop antibiotics earlier than usual. About 136 children will be randomly assigned to either stop antibiotics within 24 hours or continue standard treatment. The goal is to se…
Phase 4 • Sponsor: Hospital Universitari Vall d'Hebron Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New oral drug could replace injections for kidney anemia
Disease control Not yet recruitingThis study tests a gradual switch from the injected drug Epogen to an oral medication called vadadustat for people with anemia who are on dialysis. The goal is to see if patients can stay on vadadustat long-term without stomach issues or drops in red blood cell levels. About 100 …
Phase 3 • Sponsor: Geoff Block • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New drug cocktail aims to boost transplant success in elderly leukemia patients
Disease control Not yet recruitingThis study tests whether a combination of three chemotherapy drugs (thiotepa, busulfan, and fludarabine) given before a stem cell transplant can help older adults with acute myeloid leukemia stay in remission longer. About 93 patients aged 55 to 75 who are in their first remissio…
Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New CAR-T therapy aims to stop High-Risk lymphoma early
Disease control Not yet recruitingThis Phase 2 trial tests a CAR-T cell therapy called zamtocabtagene autoleucel as a first-line consolidation treatment for people with high-risk mantle cell lymphoma. About 52 participants will receive the therapy after standard chemotherapy. The main goal is to see how long they…
Phase 2 • Sponsor: Miltenyi Biomedicine GmbH • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Immune cell boost may keep leukemia at bay after transplant
Disease control Not yet recruitingThis study tests a stem cell transplant from a matched sibling donor combined with special immune cells (regulatory and conventional T cells) for people with high-risk acute myeloid leukemia (AML). The goal is to prevent the cancer from coming back. About 28 participants will rec…
Phase 2 • Sponsor: Antonio Pierini • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Chemo-free triplet aims to outsmart incurable lymphoma
Disease control Not yet recruitingThis study tests a chemotherapy-free combination of three drugs (sonrotoclax, zanubrutinib, and rituximab) in 52 adults with previously untreated follicular lymphoma. The goal is to see if this approach can produce deeper and longer-lasting remissions while being easier to tolera…
Phase 2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug duo takes on Hard-to-Treat waldenstrom macroglobulinemia
Disease control Not yet recruitingThis phase II trial is testing the safety and effectiveness of combining two drugs, mosunetuzumab and pirtobrutinib, in 25 adults with relapsed or refractory Waldenstrom Macroglobulinemia, a rare blood cancer. Participants must have had at least one prior treatment. The study aim…
Phase 2 • Sponsor: University of Utah • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New cocktail of drugs shows promise against rare lymphoma
Disease control Not yet recruitingThis study is testing a combination of three drugs—sintilimab, chidamide, and azacitidine—as a first treatment for people with early-stage extranodal NK/T-cell lymphoma, a rare blood cancer. About 30 participants will receive the drugs, and their response will guide further treat…
Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New hope for tough leukemia: precision drug combo trial launches
Disease control Not yet recruitingThis phase 2 trial tests whether personalized drug combinations can help people with relapsed or treatment-resistant T-cell acute lymphoblastic leukemia (T-ALL). Researchers will assign patients to one of several targeted therapies based on lab tests. The main goal is to see if t…
Phase 2 • Sponsor: Philippe ROUSSELOT • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New drug cocktail takes on rare skin cancer
Disease control Not yet recruitingThis Phase II trial tests a new drug called VG712 against an existing drug, mogamulizumab, in about 386 people with advanced mycosis fungoides, a rare type of skin lymphoma. VG712 is designed to kill cancerous immune cells by blocking protein production. The study aims to see if …
Phase 2 • Sponsor: Virogen Biotechnology Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Triple-Drug combo aims to stop AML relapse after remission
Disease control Not yet recruitingThis study tests whether a combination of three drugs (chidamide, venetoclax, and azacitidine) can help prevent acute myeloid leukemia (AML) from coming back in patients who have already achieved remission. About 104 adults aged 18 to 80 will receive up to 12 cycles of treatment.…
Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Could a common diabetes pill treat anemia in MDS patients?
Disease control Not yet recruitingThis study tests whether dapagliflozin, a drug used for diabetes, can help treat anemia in people with lower-risk myelodysplastic syndromes (MDS). Anemia is a common problem in MDS, causing fatigue and often requiring blood transfusions. The trial will give 37 participants dapagl…
Phase 2 • Sponsor: Seug yun Yoon, MD • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New cell therapy aims to supercharge Kids' immune cells after transplant
Disease control Not yet recruitingThis early-phase trial tests a new cell therapy called ThINKK in 12 children aged 2–12 who have had a stem cell transplant for leukemia or neuroblastoma. The therapy is designed to boost the body's natural killer (NK) cells to better fight cancer. The main goals are to check if t…
Phase 1 • Sponsor: Michel Duval • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New combo aims to tame autoimmune anemia without Long-Term steroids
Disease control Not yet recruitingThis study tests whether adding sirolimus to standard steroid treatment helps people with newly diagnosed mild autoimmune hemolytic anemia (AIHA) achieve lasting remission. About 216 adults will be randomly assigned to get either steroids alone or steroids plus sirolimus for 6 mo…
Sponsor: Chen Miao • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New CAR T-Cell therapy targets Hard-to-Treat multiple myeloma in early trial
Disease control Not yet recruitingThis early-stage study tests a new treatment called Equecabtagene autoleucel for people with multiple myeloma that has returned or stopped responding to at least three prior therapies. The treatment uses a patient's own immune cells, modified to attack a protein called BCMA on my…
Phase 1/2 • Sponsor: Nanjing IASO Biotechnology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New hope for elderly AML patients: drug combo aims to control disease without harsh chemo
Disease control Not yet recruitingThis study tests a combination of three drugs (venetoclax, homoharringtonine, and azacitidine) plus a growth factor (G-CSF) in 61 older or frail adults with newly diagnosed acute myeloid leukemia (AML) who cannot tolerate standard intensive chemotherapy. The goal is to see if thi…
Phase 2 • Sponsor: First People's Hospital of Hangzhou • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New Triple-Drug attack on aggressive leukemia shows promise in major trial
Disease control Not yet recruitingThis study tests whether a three-drug combination (venetoclax, azacitidine, and gilteritinib) followed by strong chemotherapy works better than standard chemotherapy plus gilteritinib for adults with a specific genetic type of acute myeloid leukemia (FLT3-mutated AML). About 300 …
Phase 3 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New combo therapy aims to keep leukemia away after transplant
Disease control Not yet recruitingThis phase 2 trial tests whether adding asciminib to standard tyrosine kinase inhibitors can prevent relapse in patients with Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia or blastic phase chronic myeloid leukemia after a stem cell transplant. 45 participan…
Phase 2 • Sponsor: The University of Hong Kong • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Early screening and care for sickle cell in newborns could save lives
Disease control Not yet recruitingThis study will test 120 babies in Côte d'Ivoire for sickle cell disease using a simple point-of-care test. Babies who test positive will start comprehensive care early, including medicines and vaccines. Researchers want to see if this approach reduces serious health problems and…
Phase 4 • Sponsor: Swiss Tropical & Public Health Institute • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Could one antibiotic replace two for chemo fevers? major trial launches
Disease control Not yet recruitingThis study compares a single antibiotic (amoxicillin-clavulanate) against the standard two-drug combination (amoxicillin-clavulanate plus ciprofloxacin) for treating fever caused by chemotherapy in adults with certain blood cancers. The goal is to see if the simpler treatment wor…
Phase 3 • Sponsor: Versailles Hospital • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New drug MTM-H-001 takes on tough blood cancers
Disease control Not yet recruitingThis early study tests a new drug called MTM-H-001 in 69 adults with B-cell blood cancers (like certain lymphomas and leukemias) that have come back or stopped responding to treatment. The main goal is to check safety and find the right dose, while also seeing if it can shrink tu…
Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Malaria drug combo under scrutiny: could tafenoquine interact?
Disease control Not yet recruitingThis study looks at whether a malaria drug called tafenoquine interacts with two other common malaria treatments (DHA-piperaquine and artesunate-pyronaridine) in adults with vivax malaria. About 507 participants will receive one of the combinations or a delayed treatment to compa…
Phase 4 • Sponsor: Menzies School of Health Research • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Blood cancer patients may get liver protection from common drug
Disease control Not yet recruitingThis real-world study looks at whether polyene phosphatidylcholine injection can prevent or treat drug-induced liver injury in adults with blood cancers like leukemia and lymphoma. Researchers will review medical records of 1,000 patients to see how well the drug works and if it …
Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Could a lower dose of blood cancer drugs be just as effective?
Disease control Not yet recruitingThis trial is for adults with multiple myeloma or Waldenstrom macroglobulinaemia. It tests whether giving certain drugs less often can control the disease as well as the standard schedule. The goal is to find the best balance between effectiveness and quality of life. About 400 p…
Phase 4 • Sponsor: Anne Louise Tølbøll Sørensen • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New combo procedure aims to fix heart rhythm and prevent stroke in one go
Disease control Not yet recruitingThis study will test a combined procedure in 150 people with atrial fibrillation (AFib) who are at risk for stroke. Doctors will use pulse field ablation to correct the heart's rhythm and then close off a small pouch in the heart (the left atrial appendage) to prevent blood clots…
Sponsor: Asklepios proresearch • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New combo aims to stop leukemia return in older patients
Disease control Not yet recruitingThis study tests whether adding ivosidenib to oral azacitidine (Onureg) can help prevent acute myeloid leukemia (AML) from coming back in people over 55 who have a specific IDH1 mutation and are already in remission after chemotherapy. About 60 participants will take both pills d…
Phase 2 • Sponsor: French Innovative Leukemia Organisation • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New drug combo may boost stem cell success in rare bone marrow cancer
Disease control Not yet recruitingThis study tests whether the drug gecacitinib, given before, during, and after a stem cell transplant, can help people with myelofibrosis (a type of bone marrow cancer) have better outcomes. About 39 adults aged 18-75 with intermediate- or high-risk myelofibrosis will take part. …
Phase 2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
Could white blood cells boost cord transplants for tough leukemia?
Disease control Not yet recruitingThis trial tests a new way to do cord blood transplants for young adults (ages 16-55) with very poor risk acute myeloid leukemia (AML). Participants get a standard cord blood transplant plus daily infusions of white blood cells called granulocytes for 1 to 7 days. The goal is to …
Phase 1/2 • Sponsor: University of Manchester • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Experimental immune cell therapy takes on Hard-to-Treat myeloma
Disease control Not yet recruitingThis early-phase trial tests a personalized cell therapy called CART-BCMA in 3 Thai patients with multiple myeloma that has returned or stopped responding to at least three prior treatments. The therapy uses the patient's own immune cells, modified in a lab to target and kill mye…
Early phase 1 • Sponsor: Chulalongkorn University • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Prostate surgery bleeding breakthrough? new drug trial aims to cut blood loss
Disease control Not yet recruitingThis study tests whether giving tranexamic acid (a drug that helps blood clot) before prostate surgery can reduce bleeding and prevent anemia in older men. About 80 men aged 50+ with enlarged prostates will receive either the drug or a placebo. The goal is to see if this simple a…
Phase 4 • Sponsor: Hamza Najout • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New hope for leukemia patients: immunotherapy added to standard care
Disease control Not yet recruitingThis study tests a new treatment plan for adults up to 65 years old with a type of leukemia called Ph-negative ALL. The goal is to see if adding an immunotherapy drug called blinatumomab improves survival compared to the previous treatment plan. About 330 participants will receiv…
Sponsor: PETHEMA Foundation • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New combo therapy targets Hard-to-Treat lymphoma
Disease control Not yet recruitingThis study tests a combination of two drugs, pomalidomide and obinutuzumab, in people with slow-growing lymphomas (like follicular lymphoma) that have returned or not responded to prior therapy. The first part finds the safest dose, and the second part checks how well the combina…
Phase 1/2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Could a gentle pill stop blood cancer before it starts?
Disease control Not yet recruitingThis study tests a low-dose oral drug (decitabine with tetrahydrouridine) in 80 adults aged 60–85 who have a high-risk blood condition called CCUS, which often leads to blood cancer. The drug aims to reduce harmful mutations in blood cells and restore normal blood production with…
Phase 2 • Sponsor: Clinical Hub for Interventional Research (CHOIR) • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New drug combo aims to prevent dangerous transplant complication in rare blood cancer
Disease control Not yet recruitingThis study tests whether a new drug called gecacitinib, combined with standard anti-rejection medicine, can prevent a serious complication called graft-versus-host disease (GVHD) in people with myelofibrosis who receive a stem cell transplant. About 40 adults will take part. The …
Sponsor: Nanfang Hospital, Southern Medical University • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New combo aims to outdo standard chemo for FLT3-Mutated leukemia
Disease control Not yet recruitingThis study tests a new three-drug combination (gilteritinib, azacitidine, and venetoclax) against standard chemotherapy for adults with a specific genetic subtype of acute myeloid leukemia (FLT3-ITD). About 230 newly diagnosed patients aged 18-75 who are healthy enough for intens…
Phase 2/3 • Sponsor: European Organisation for Research and Treatment of Cancer - EORTC • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Could an arthritis drug boost leukemia treatment?
Disease control Not yet recruitingThis early-phase trial tests adding tocilizumab, a drug used for arthritis, to standard chemotherapy (azacitidine and venetoclax) for adults with acute myeloid leukemia (AML) who cannot have intensive treatment. The main goal is to find a safe dose and check for side effects. Onl…
Phase 1 • Sponsor: Nantes University Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Colombia launches first CAR-T trial for Hard-to-Treat blood cancers
Disease control Not yet recruitingThis study aims to bring CAR-T cell therapy to Colombia for people with certain blood cancers that have come back or not responded to treatment. It has two parts: first, setting up the necessary partnerships and facilities to produce the therapy locally, and second, testing the s…
Sponsor: GUSTAVO SALGUERO • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New hope for brain cancer: targeted drug combo shows promise
Disease control Not yet recruitingThis phase 2 trial tests a combination of zanubrutinib (a targeted drug) plus chemotherapy for people newly diagnosed with central nervous system lymphoma. Nineteen participants will receive the treatment, with an extra drug for those with a specific gene mutation. The goal is to…
Phase 2 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New combo attack on hard-to-treat myeloma enters human testing
Disease control Not yet recruitingThis early-phase study tests whether giving a bispecific antibody (CM336) before CAR-T cell therapy can improve outcomes for people with relapsed or refractory multiple myeloma — a blood cancer that has stopped responding to standard treatments. Ten adults will receive the antibo…
Phase 1 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New drug cocktail aims to tame rare bleeding disorder
Disease control Not yet recruitingThis phase 2 study tests whether combining orelabrutinib (a targeted drug) with romiplostim (a platelet booster) can improve platelet counts in adults with chronic immune thrombocytopenia (ITP) who haven't responded well to standard treatments. About 28 participants will receive …
Phase 2 • Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New CAR T-Cell therapy takes on Hard-to-Treat myeloma
Disease control Not yet recruitingThis early-phase trial tests a new treatment called LVIVO-TaVec400 for people with multiple myeloma that has come back or not responded to standard treatments. The therapy uses the patient's own immune cells, modified to better attack cancer cells. The study will enroll 38 adults…
Early phase 1 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New antibody drug may boost transplant success in tough lymphoma
Disease control Not yet recruitingThis phase 2 trial tests glofitamab, an antibody that helps immune cells attack lymphoma, in 40 adults with relapsed or refractory diffuse large B-cell lymphoma who are eligible for a stem cell transplant. Glofitamab is given before transplant as a 'bridge' to shrink the cancer, …
Phase 2 • Sponsor: American University of Beirut Medical Center • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
New drug aims to stop deadly transplant complication
Disease control Not yet recruitingThis study tests a drug called ivarmacitinib to prevent acute graft-versus-host disease (aGVHD) in 32 people with blood cancers receiving a half-matched stem cell transplant. The goal is to see if the drug can lower the chance of severe GVHD and improve survival without long-term…
Phase 1/2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New shot targets leukemia that chemo Can't beat
Disease control Not yet recruitingThis study tests an experimental antibody drug called A-319 for people with a type of leukemia (B-ALL) that has come back or not fully cleared after chemotherapy. The drug is given as a shot under the skin and aims to help the immune system attack cancer cells. The main goals are…
Sponsor: Shanxi Bethune Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Engineered immune cells take on tough leukemia in new trial
Disease control Not yet recruitingThis early-phase study tests a new type of CAR-T cell therapy for adults with acute myeloid leukemia (AML) that has come back or not responded to standard treatments. The therapy uses a patient's own immune cells, modified to better find and attack leukemia cells. The main goal i…
Phase 1/2 • Sponsor: Xuzhou Medical University • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New hope for kids: drug combo aims to stop transplant complications
Disease control Not yet recruitingThis early-phase study tests whether adding an experimental drug (VIC-1911) to standard medications can prevent graft-versus-host disease (GVHD) in children aged 8-18 who receive a stem cell transplant from a half-matched donor. GVHD occurs when donor cells attack the child's bod…
Phase 1 • Sponsor: Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New CAR-T therapy aims to control Hard-to-Treat lymphoma
Disease control Not yet recruitingThis study tests a new treatment called TC011 for adults with follicular lymphoma that has come back or not responded to at least two prior therapies. TC011 is a type of CAR-T cell therapy that targets cancer cells. The main goal is to see how many patients' tumors shrink or disa…
Phase 2 • Sponsor: TICAROS Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Can a Tumor's DNA reveal the best lymphoma treatment?
Diagnosis Not yet recruitingResearchers at M.D. Anderson Cancer Center are testing whether comprehensive genomic sequencing can identify specific subtypes of large B-cell lymphoma and provide information that may help guide treatment decisions. The trial enrolls about 60 adults with stage 3 or 4 diffuse lar…
Sponsor: M.D. Anderson Cancer Center • Aim: Diagnosis
Last updated Sep 21, 2026 20:00 UTC
-
Your phone as a stethoscope: can an app spot hidden heart valve disease?
Diagnosis Not yet recruitingResearchers are testing whether a smartphone app called Stethophone can help primary care doctors find moderate or severe aortic stenosis in adults aged 70 and older. The app turns a phone into a digital stethoscope and analyzes heart sounds for murmurs that may signal the condit…
Sponsor: Sunnybrook Health Sciences Centre • Aim: Diagnosis
Last updated Sep 20, 2026 00:00 UTC
-
Breath test aims to classify leukaemia in hours, not days
Diagnosis Not yet recruitingDoctors often wait days for genetic tests to classify acute myeloid leukaemia (AML) and guide treatment. This trial tests whether breath analysis can detect metabolic products from leukaemia and classify the disease faster. Participants give breath samples and extra blood tests d…
Sponsor: Jeremy Deuel • Aim: Diagnosis
Last updated Sep 19, 2026 00:00 UTC
-
AI second pair of eyes could speed up finding hidden bleeding
Diagnosis Not yet recruitingResearchers are testing an AI software tool called DSA-VDet v1.0 that highlights suspected bleeding on angiography images in real time. The trial enrolls adults with suspected acute bleeding in various body regions who need a digital subtraction angiography (DSA) procedure. Docto…
Sponsor: Zhongda Hospital • Aim: Diagnosis
Last updated Sep 19, 2026 00:00 UTC
-
DNA test for infections: can it guide antibiotic decisions?
Diagnosis Not yet recruitingResearchers are running a large observational registry to see how a blood test called metagenomic sequencing is used in routine care for people with or at risk of serious infections, including those with weakened immune systems. The study enrolls participants at multiple hospital…
Sponsor: Karius, Inc. • Aim: Diagnosis
Last updated Sep 19, 2026 00:00 UTC
-
Smart wristbands may spot malaria before symptoms strike
Diagnosis Not yet recruitingThis early-stage study tests whether wearable biosensors (like a wristband or earphones) can detect malaria infection before symptoms appear. 32 healthy adults will be exposed to the malaria parasite or a placebo in a controlled setting. Researchers will compare biosensor reading…
Phase 1 • Sponsor: University of Maryland, Baltimore • Aim: Diagnosis
Last updated Sep 11, 2026 00:00 UTC
-
Painless blood test could replace bone marrow biopsy for MPN patients
Diagnosis Not yet recruitingThis study aims to develop a new blood test that could replace the invasive bone marrow biopsy currently used to diagnose myeloproliferative neoplasms (MPNs), a group of blood cancers. Researchers will collect blood samples from 500 adults with suspected or confirmed MPN and anal…
Sponsor: Weizmann Institute of Science • Aim: Diagnosis
Last updated Sep 03, 2026 00:00 UTC
-
Smartwatch signals may flag anemia, no needle needed
Diagnosis Not yet recruitingAnemia often goes unnoticed because diagnosis requires a blood draw. This study tests whether a wrist-worn smartwatch can identify people likely to have anemia by tracking blood flow, heart rate, oxygen, and movement. About 400 adults, with and without anemia, will wear the watch…
Sponsor: Peking Union Medical College Hospital • Aim: Diagnosis
Last updated Sep 03, 2026 00:00 UTC
-
AI takes on the experts: a test for diagnosing mycosis fungoides
Diagnosis Not yet recruitingThis study asks whether an artificial intelligence algorithm can diagnose mycosis fungoides, a rare type of skin lymphoma, from biopsy slides as accurately as certified dermatopathologists. Researchers will compare the AI's sensitivity and specificity against expert readings usin…
Sponsor: Al-Azhar University • Aim: Diagnosis
Last updated Sep 02, 2026 00:00 UTC
-
Needle-Free anemia detection for fragile newborns?
Diagnosis Not yet recruitingThis study tests whether a non-invasive sensor placed on the skin can accurately measure hemoglobin levels in infants in the neonatal intensive care unit (NICU). The sensor uses light to estimate hemoglobin without any needle sticks, which could reduce pain and blood loss in thes…
Sponsor: University of Malaya • Aim: Diagnosis
Last updated Aug 28, 2026 00:00 UTC
-
Urine and MRI: a new hope for spotting silent kidney injury in sickle cell kids?
Diagnosis Not yet recruitingThis study investigates whether urine tests for two biomarkers (NAG and KIM-1) and special MRI scans can detect early kidney damage in children with sickle cell disease. The goal is to find a way to identify kidney problems before they become serious, potentially allowing earlier…
Sponsor: Assiut University • Aim: Diagnosis
Last updated Aug 27, 2026 00:00 UTC
-
Can a bedside ultrasound predict a deadly sickle cell complication?
Diagnosis Not yet recruitingThis study tests whether a bedside lung ultrasound, done within six hours of arriving at the emergency department, can help diagnose acute chest syndrome in adults with sickle cell disease experiencing a vaso-occlusive crisis. Acute chest syndrome is a serious lung complication t…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Diagnosis
Last updated Aug 26, 2026 00:00 UTC
-
A 5-Day genetic test could slash time to transplant for children with rare immune disease
Diagnosis Not yet recruitingThis trial tests whether a new ultra-rapid genetic test, using third-generation sequencing, can diagnose familial lymphohistiocytosis (FHL) in children within 5 days instead of the usual 6-8 weeks. FHL is a rare, life-threatening genetic condition where the immune system attacks …
Sponsor: Assistance Publique Hopitaux De Marseille • Aim: Diagnosis
Last updated Aug 05, 2026 00:00 UTC
-
Hours, not weeks: a new test could speed up lymphoma diagnosis
Diagnosis Not yet recruitingThis trial tests whether a rapid lab technique called flow cytometry can quickly identify lymphoma from a small lymph node sample. People already undergoing a standard fine needle aspiration for suspected lymphoma will give an extra sample for this test. The goal is to see if thi…
Sponsor: The Clatterbridge Cancer Centre NHS Foundation Trust • Aim: Diagnosis
Last updated Aug 02, 2026 00:00 UTC
-
Genetic blood test could spare many pregnancies from unnecessary monitoring
Diagnosis Not yet recruitingThis study tests whether a blood test using next-generation sequencing (NGS) can accurately determine the blood type of an unborn baby. In about 1% of pregnancies, the mother's immune system produces antibodies that can attack the baby's red blood cells, potentially causing anemi…
Sponsor: Karolinska University Hospital • Aim: Diagnosis
Last updated Jul 22, 2026 00:00 UTC
-
New imaging tracer could spot hidden cancers and fibrosis in one scan
Diagnosis Not yet recruitingThis study tests a new imaging tracer called [18F]FAPI-74, which attaches to a protein found on cells in tumors and scarred or inflamed tissue. Researchers want to see if it can show these areas more clearly than current scans. About 770 adults with various cancers or non-cancer …
Phase 1/2 • Sponsor: Martin Huellner • Aim: Diagnosis
Last updated Jul 17, 2026 00:00 UTC
-
Could a painless light sensor replace the needle for anemia screening?
Diagnosis Not yet recruitingThis study tests whether a non-invasive device that uses light to measure hemoglobin through the skin can accurately detect anemia. Researchers will compare its readings with standard blood tests in 150 adults in Jakarta. If the device proves reliable, it could offer a quick, pai…
Sponsor: Tarumanagara University • Aim: Diagnosis
Last updated Jul 17, 2026 00:00 UTC
-
AI blood test could spot deadly clotting complication in sepsis patients
Diagnosis Not yet recruitingThis study aims to validate a new blood test that uses artificial intelligence to detect disseminated intravascular coagulation (DIC) early in patients with septic shock. DIC is a severe clotting disorder that often leads to death, but current diagnostic methods are complex and r…
Sponsor: University Hospital, Strasbourg, France • Aim: Diagnosis
Last updated Jun 27, 2026 13:03 UTC
-
New scan spots hidden organ damage before symptoms start
Diagnosis Not yet recruitingThis study explores whether a PET/MR scan using a radioactive tracer called 18F-Florbetaben can detect amyloid deposits—abnormal protein clumps that can damage organs—in people with certain blood disorders. Participants receive a single injection of the tracer followed by a whole…
Sponsor: University of Zurich • Aim: Diagnosis
Last updated Jun 27, 2026 13:00 UTC
-
New scan may better spot hidden cancer in lymph nodes
Diagnosis Not yet recruitingThis study will compare two different PET/MRI scans to see which one is better at finding lymph node metastases in people with middle to high rectal cancer. Thirty participants will receive both types of scans before surgery. The goal is to see if the newer tracer, [68Ga]Ga-CTR-F…
Sponsor: Peking University Cancer Hospital & Institute • Aim: Diagnosis
Last updated Jun 27, 2026 12:29 UTC
-
Needle-Free hope: ultrasound may spot dangerous liver pressure
Diagnosis Not yet recruitingThis study tests whether a combination of contrast-enhanced ultrasound and spleen stiffness measurement can accurately detect high blood pressure in the liver (portal hypertension) in people with cirrhosis. Currently, doctors must insert a catheter into a neck vein to measure thi…
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Diagnosis
Last updated Jun 27, 2026 08:14 UTC
-
Tweaking donor cells may shield older transplant patients from a dangerous complication
Prevention Not yet recruitingResearchers are testing whether removing a specific type of immune cell, called CD45RA-positive naive T cells, from donor stem cells can prevent graft-versus-host disease in older adults undergoing stem cell transplants for acute leukemia or myelodysplastic syndrome. The trial en…
Phase 2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Prevention
Last updated Sep 16, 2026 00:00 UTC
-
School-Based malaria treatment could slash community infections
Prevention Not yet recruitingThis study tests whether giving malaria medicine to school-age children can lower malaria cases in the entire community. School children often carry the malaria parasite without symptoms and spread it to others. The trial will involve about 4,800 children in The Gambia and measur…
Phase 4 • Sponsor: University of California, San Francisco • Aim: Prevention
Last updated Sep 13, 2026 00:00 UTC
-
Aloe vera mouthwash tested against chemotherapy mouth sores
Prevention Not yet recruitingResearchers are studying whether aloe vera mouthwash can prevent or reduce the severity of oral mucositis, a painful mouth sore that often affects people receiving chemotherapy for acute leukemia. The trial compares aloe vera mouthwash plus usual care against usual care alone in …
Sponsor: Wake Forest University Health Sciences • Aim: Prevention
Last updated Sep 11, 2026 00:00 UTC
-
Can a new drug stop the Body's attack after stem cell transplants?
Prevention Not yet recruitingThis phase II trial tests whether adding axatilimab to standard care can prevent graft-versus-host disease (GVHD), a serious complication where donor immune cells attack the recipient's body after a stem cell transplant. Adults with blood cancers receiving a myeloablative allogen…
Phase 2 • Sponsor: Medical College of Wisconsin • Aim: Prevention
Last updated Sep 10, 2026 00:00 UTC
-
Vitamin K2 drops could shield breastfed infants from bleeding risk
Prevention Not yet recruitingThis study tests whether giving vitamin K2 (MK-7) supplements to breastfed infants or their breastfeeding mothers can prevent vitamin K deficiency at 2 months of age. About 134 healthy, full-term babies who received standard vitamin K shots at birth will be enrolled. Some infants…
Sponsor: Norfolk and Norwich University Hospitals NHS Foundation Trust • Aim: Prevention
Last updated Sep 06, 2026 00:00 UTC
-
Can monthly malaria pills sharpen Children's minds?
Prevention Not yet recruitingThis trial tests whether giving schoolchildren in Kenya an antimalarial drug every month, instead of every three months, better protects their brain function and school performance. Researchers will enroll 1,500 children aged 6 to 10 from six primary schools. Half will receive mo…
Phase 3 • Sponsor: Indiana University • Aim: Prevention
Last updated Sep 03, 2026 00:00 UTC
-
Routine iron after childbirth: which guideline works best?
Prevention Not yet recruitingThis trial compares two common guidelines for giving iron supplements to mothers after childbirth who already have normal hemoglobin levels. One group receives daily iron for six weeks, while the other does not. The goal is to see which approach better prevents postpartum anemia …
Sponsor: Sana Nadeem Qasir • Aim: Prevention
Last updated Aug 07, 2026 00:00 UTC
-
Could a simple device help curb malaria in children?
Prevention Not yet recruitingThis study tests whether a device called the Guardian spatial emanator, which releases mosquito-repelling ingredients into the air, can be effectively added to an existing program that distributes antibiotics to children in Niger. The goal is to see if this integrated approach ca…
Sponsor: University of California, San Francisco • Aim: Prevention
Last updated Jul 24, 2026 00:00 UTC
-
New trial aims to shield hearts from chemo side effects
Prevention Not yet recruitingThis study tests whether a drug called sotagliflozin can prevent heart, muscle, and fat damage caused by a common type of chemotherapy (anthracycline) in people with newly diagnosed lymphoma. About 60 adults who are scheduled to receive high-dose anthracycline will take either th…
Phase 2 • Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Prevention
Last updated Jun 27, 2026 12:30 UTC
-
Could a simple device keep mosquitoes away better than spraying?
Prevention Not yet recruitingThis study tests new devices called LASER that release a chemical to repel mosquitoes, comparing them to indoor insecticide spraying and standard prevention (bed nets, vaccines). About 22,800 people in 69 Kenyan villages will take part over two years. Researchers will check malar…
Sponsor: Liverpool School of Tropical Medicine • Aim: Prevention
Last updated Jun 27, 2026 09:01 UTC
-
Light therapy may soothe chemo mouth sores in children
Prevention Not yet recruitingThis study tests if a special light (photobiomodulation) can prevent and treat painful mouth sores caused by chemotherapy in children aged 4-17 with cancer. Half of the 49 participants will get light therapy, and the other half will get a standard gel. The goal is to see if the l…
Sponsor: Universidad de Guanajuato • Aim: Prevention
Last updated Jun 27, 2026 09:00 UTC
-
Mindfulness on your phone: a new test for sickle cell pain and sleep
Symptom relief Not yet recruitingThis trial tests whether a smartphone-based mindfulness program can help adolescents and young adults with sickle cell disease manage chronic pain and sleep problems. Participants are randomly assigned to either use the mindfulness app for about 8 weeks or receive usual care. The…
Sponsor: University of Illinois at Chicago • Aim: Symptom relief
Last updated Sep 21, 2026 20:00 UTC
-
Can adding common pain drugs reduce morphine needs in sickle cell crises?
Symptom relief Not yet recruitingAdults with sickle cell disease often face severe pain crises that require hospital treatment with intravenous morphine. This trial compares standard morphine treatment with combinations that add paracetamol, ketamine, or nefopam. Researchers want to see if these combinations eas…
Phase 4 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Symptom relief
Last updated Sep 20, 2026 00:00 UTC
-
Can spiritual workshops ease Cancer's existential pain?
Symptom relief Not yet recruitingThis study tests a spiritual health program called PATH for cancer patients struggling with feelings of disconnection, loss of meaning, or existential distress. Twenty adults with any stage of cancer will attend six workshops combining role-playing, psychology, and dignity therap…
Sponsor: Fred Hutchinson Cancer Center • Aim: Symptom relief
Last updated Sep 19, 2026 00:00 UTC
-
Can a single psychedelic dose ease despair in advanced cancer?
Symptom relief Not yet recruitingResearchers are testing whether a single high dose of psilocybin, given alongside a structured talking therapy called PEARL, reduces depressive symptoms in adults with advanced cancer. The trial enrolls 46 people in Ontario with stage IV solid tumors, sarcoma, melanoma, endocrine…
Phase 2 • Sponsor: University Health Network, Toronto • Aim: Symptom relief
Last updated Sep 17, 2026 00:00 UTC
-
Can IV iron boost blood levels and daily energy for mothers before and after delivery?
Symptom relief Not yet recruitingAnemia from iron deficiency is common in pregnancy and after childbirth, affecting many women. This trial tests whether iron given through a vein can raise hemoglobin levels and improve how women feel and function in everyday life before and after delivery. Researchers will compa…
Sponsor: Johann Wolfgang Goethe University Hospital • Aim: Symptom relief
Last updated Sep 13, 2026 00:00 UTC
-
Strumming through treatment: can ukulele lessons shield teen brains from Radiation's toll?
Symptom relief Not yet recruitingThis pilot trial tests whether a program of virtual ukulele lessons, called STRUM, can help teenagers preserve cognitive function and emotional resilience while undergoing radiation therapy for cancer. The study enrolls adolescents aged 12 to 17 who are receiving initial radiatio…
Sponsor: Mayo Clinic • Aim: Symptom relief
Last updated Sep 13, 2026 00:00 UTC
-
A phone call from a survivor: could peer support calm transplant anxiety?
Symptom relief Not yet recruitingThis trial tests whether a structured peer support program, called STEPP, can reduce anxiety and improve quality of life in adults undergoing stem cell transplantation for blood cancers. Participants receive five phone sessions with a trained transplant survivor, blending cogniti…
Sponsor: Brigham and Women's Hospital • Aim: Symptom relief
Last updated Sep 12, 2026 00:00 UTC
-
Can a 5-minute video or a game teach kids with sickle cell to fight pain crises?
Symptom relief Not yet recruitingThis trial tests whether short educational videos or interactive games can empower children with sickle cell disease. The goal is to help kids aged 12 to 18 understand their condition and build skills for self-care and managing pain. Researchers will measure changes in self-effic…
Sponsor: Aula Ibrahim abd alrazak • Aim: Symptom relief
Last updated Sep 05, 2026 00:00 UTC
-
Could virtual reality help patients recover faster from cell therapy?
Symptom relief Not yet recruitingThis study tests whether using an immersive virtual reality headset during exercise can improve motivation, adherence, and emotional well-being in adults undergoing cell therapy or stem cell transplant. Participants follow a therapeutic exercise program with or without VR. The tr…
Sponsor: Fundacin Biomedica Galicia Sur • Aim: Symptom relief
Last updated Sep 04, 2026 00:00 UTC
-
Can a single buprenorphine dose tame sickle cell pain?
Symptom relief Not yet recruitingThis trial tests whether a single dose of buprenorphine, given as a film inside the cheek, is safe and helps control pain in adolescents and young adults with sickle cell disease who are hospitalized for a pain crisis. Participants receive one dose of buprenorphine instead of sta…
Phase 1 • Sponsor: Natasha Archer • Aim: Symptom relief
Last updated Sep 04, 2026 00:00 UTC
-
Can a common antipsychotic keep cannabis users out of the ER?
Symptom relief Not yet recruitingThis trial tests whether giving patients a prescription for haloperidol to use as needed at home can help control symptoms of cannabinoid hyperemesis syndrome — a condition marked by severe nausea, vomiting, and abdominal pain from heavy cannabis use. The goal is to see if having…
Early phase 1 • Sponsor: University of Illinois at Chicago • Aim: Symptom relief
Last updated Sep 03, 2026 00:00 UTC
-
New pill aims to boost red blood cells in cancer patients
Symptom relief Not yet recruitingThis Phase 2 trial tests an oral drug called AND017 for anemia (low red blood cells) in cancer patients who are not receiving chemotherapy. The study will enroll 36 participants to see if different doses of AND017 can safely raise hemoglobin levels over 6 weeks. The goal is to re…
Phase 2 • Sponsor: Kind Pharmaceuticals LLC • Aim: Symptom relief
Last updated Sep 03, 2026 00:00 UTC
-
New pill aims to beat chemo fatigue: AND017 trial launches
Symptom relief Not yet recruitingThis Phase 2 trial tests an oral drug called AND017 for cancer-related anemia caused by chemotherapy. About 36 adults with non-myeloid cancers and low hemoglobin will take AND017 three times a week for 6 weeks. The goal is to see if it safely raises hemoglobin levels and reduces …
Phase 2 • Sponsor: Kind Pharmaceuticals LLC • Aim: Symptom relief
Last updated Sep 03, 2026 00:00 UTC
-
Can a high fiber diet ease transplant recovery?
Symptom relief Not yet recruitingThis pilot study tests whether a dietitian-led High Fiber Program can help patients increase their fiber intake after receiving a stem cell transplant from a donor. The goal is to improve gut health and possibly reduce complications like graft-versus-host disease. About 44 adults…
Sponsor: City of Hope Medical Center • Aim: Symptom relief
Last updated Sep 02, 2026 00:00 UTC
-
Can a smart order system ensure older AML patients get the support they need?
Symptom relief Not yet recruitingThis trial tests a method called Active Default to improve supportive care for adults 60 and older starting venetoclax-based therapy for acute myeloid leukemia (AML). Participants complete a geriatric assessment covering mobility, nutrition, mood, memory, and medications. If the …
Sponsor: University of Alabama at Birmingham • Aim: Symptom relief
Last updated Aug 23, 2026 00:00 UTC
-
Art as medicine: can drawing and painting help sick kids feel better about themselves?
Symptom relief Not yet recruitingThis trial tests whether a structured art therapy program, grounded in positive psychology, can improve self-compassion and hope in children aged 8 to 12 who are staying in a hospital ward. Half of the 80 participants will receive the art therapy sessions alongside standard nursi…
Sponsor: Suleyman Demirel University • Aim: Symptom relief
Last updated Aug 21, 2026 00:00 UTC
-
Can a VR app ease the pain of sickle cell disease? new study aims to find out
Symptom relief Not yet recruitingThis study tests a virtual reality app called Amani designed to help adults with sickle cell disease manage pain, emotional distress, and social isolation. Researchers will enroll 40 adults to see if the app is easy to use and helpful for improving coping skills and peer support.…
Phase 1/2 • Sponsor: Massachusetts General Hospital • Aim: Symptom relief
Last updated Aug 09, 2026 00:00 UTC
-
Zapping pain without drugs: brain stimulation put to the test for nerve pain
Symptom relief Not yet recruitingThis trial tests whether a non-invasive brain stimulation technique called temporal interference stimulation (tTIS) can reduce neuropathic pain—pain caused by nerve damage. Researchers will monitor changes in pain levels and brain plasticity in 60 adults with peripheral neuropath…
Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Symptom relief
Last updated Aug 01, 2026 00:00 UTC
-
Could a Low-Dose antipsychotic ease long COVID brain fog?
Symptom relief Not yet recruitingThis study tests whether a low dose of aripiprazole, a drug used for psychiatric conditions, can reduce fatigue and improve thinking in adults with Long COVID or other post-infection syndromes. About 138 participants will receive either the drug or a placebo for 8 weeks, then swi…
Phase 2 • Sponsor: Christiana Franke • Aim: Symptom relief
Last updated Jul 22, 2026 00:00 UTC
-
Could a VR headset ease sickle cell pain?
Symptom relief Not yet recruitingThis study explores whether using a virtual reality headset can help reduce pain for adults with sickle cell disease during a painful crisis. Participants will try different types of headset experiences—like watching a 2D video or exploring a 3D world—during their infusion center…
Sponsor: University of Maryland, Baltimore • Aim: Symptom relief
Last updated Jul 01, 2026 00:00 UTC
-
Could a bone drug ease pain in kids with rare inflammatory disease?
Symptom relief Not yet recruitingThis study tests whether the drug zoledronate can reduce pain in children aged 4 to 17 with chronic recurrent multifocal osteomyelitis (CRMO), a rare auto-inflammatory bone disease. The 30 participants have not responded to standard anti-inflammatory drugs. They will receive eith…
Phase 2 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Symptom relief
Last updated Jun 27, 2026 14:03 UTC
-
Talking therapy could help thalassemia patients take their meds
Symptom relief Not yet recruitingThis study tests whether motivational interviewing, a type of counseling, can help adults with beta-thalassemia major follow their iron chelation therapy more consistently. Forty-five participants in Oman will receive three one-on-one sessions with a nurse over six to eight weeks…
Sponsor: Oman Ministry of Health • Aim: Symptom relief
Last updated Jun 27, 2026 14:01 UTC
-
Can zoom workouts help older cancer patients in the countryside?
Symptom relief Not yet recruitingThis study tests whether a 12-week exercise program, delivered via Zoom, is practical and helpful for older adults (65+) with cancer who live in rural areas. Participants will do two supervised exercise sessions per week. The goal is to see if the program improves quality of life…
Sponsor: University of Saskatchewan • Aim: Symptom relief
Last updated Jun 27, 2026 13:01 UTC
-
Robot dog brings joy to kids battling blood cancer
Symptom relief Not yet recruitingThis study tests whether a robotic dog named AIBO can improve emotional well-being and quality of life in children aged 8-15 with blood cancers who are undergoing a stem cell transplant. The children will interact with AIBO while isolated in the hospital for about 30 days. Resear…
Sponsor: Koç University • Aim: Symptom relief
Last updated Jun 27, 2026 12:38 UTC
-
Online strength training tested to keep older cancer survivors moving
Symptom relief Not yet recruitingThis study tests whether live, online group strength training can help older cancer survivors (age 65+) who have trouble with daily activities. 150 participants will be split into three groups: immediate strength training, delayed strength training, or stretching. The goal is to …
Sponsor: OHSU Knight Cancer Institute • Aim: Symptom relief
Last updated Jun 27, 2026 12:38 UTC
-
Light therapy offers hope for kids suffering chemo mouth sores
Symptom relief Not yet recruitingThis study tests a painless light treatment called photobiomodulation for children aged 3 to 14 who get severe mouth sores from chemotherapy. The treatment uses a handheld red light device for about 5-10 minutes daily for four days, alongside standard care. Researchers want to se…
Sponsor: Tata Memorial Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 12:36 UTC
-
Ginger vs. heavy periods: a natural approach for women with bleeding disorders
Symptom relief Not yet recruitingThis study tests whether taking ginger powder for the first three days of each period can reduce heavy menstrual bleeding in women with coagulation disorders (bleeding problems). 74 women will be randomly assigned to receive either ginger or a placebo for six cycles. The goal is …
Early phase 1 • Sponsor: University of Valladolid • Aim: Symptom relief
Last updated Jun 27, 2026 12:35 UTC
-
New gel could ease jaw pain while you sleep
Symptom relief Not yet recruitingThis study tests a special gel (HA35) applied to the jaw at night to relieve pain and muscle tightness from temporomandibular joint disorder (TMD). About 30 adults with TMD will use the gel nightly for 8-12 hours. Researchers will check how well it reduces pain and tension after …
Sponsor: Nakhia Impex LLC • Aim: Symptom relief
Last updated Jun 27, 2026 12:34 UTC
-
Could an old antibiotic shield the brain in sickle cell disease?
Symptom relief Not yet recruitingThis study tests whether minocycline, an antibiotic that reduces brain inflammation, can safely prevent or reverse memory and thinking problems in adults with sickle cell disease. About 30 participants will take either a low dose, high dose, or placebo for one year. Researchers w…
Phase 1 • Sponsor: University of Cincinnati • Aim: Symptom relief
Last updated Jun 27, 2026 12:34 UTC
-
Which iron pill works best? new study aims to find out
Symptom relief Not yet recruitingThis study compares two types of iron supplements—standard ferrous salt and a newer liposomal form—in adult women with iron-deficiency anemia caused by heavy menstrual bleeding. About 100 women will take one of three treatments daily or every other day for three months. Researche…
Phase 3 • Sponsor: Hospital General de Mexico • Aim: Symptom relief
Last updated Jun 27, 2026 12:24 UTC
-
Personalized exercise shows promise for fatigue in rare blood cancers
Symptom relief Not yet recruitingThis study tests whether a 12-week personalized exercise program can reduce fatigue and improve physical function in people with myeloproliferative neoplasms (MPN) and chronic myeloid leukemia (CML). Participants will do supervised aerobic and resistance training twice a week plu…
Sponsor: Carmen Fava • Aim: Symptom relief
Last updated Jun 27, 2026 12:05 UTC
-
New hope for sickle cell pain: could iloprost cut opioid use?
Symptom relief Not yet recruitingThis study tests if iloprost, a drug that widens blood vessels and reduces inflammation, can help adults with sickle cell disease during painful vaso-occlusive crises. About 144 participants hospitalized for a crisis will receive either iloprost or a placebo, plus standard care. …
Phase 3 • Sponsor: University Hospital, Rouen • Aim: Symptom relief
Last updated Jun 27, 2026 12:00 UTC
-
ER iron infusion could get anemic kids home faster
Symptom relief Not yet recruitingThis study looks at whether giving iron through an IV in the emergency department can help children with iron deficiency anemia recover faster than taking iron pills. Researchers will compare how quickly anemia resolves, how many children need blood transfusions or hospital stays…
Phase 4 • Sponsor: Children's Hospital of Orange County • Aim: Symptom relief
Last updated Jun 27, 2026 09:05 UTC
-
Gut-Brain connection: probiotic trial aims to sharpen aging minds
Symptom relief Not yet recruitingThis study tests whether taking a specific probiotic (Lactobacillus rhamnosus GG) with a special form of vitamin B2 for 12 weeks can improve memory and thinking in adults over 65 who have mild memory problems. Researchers will measure changes in cognitive tests and brain activity…
Sponsor: Center for Health Sciences, Serbia • Aim: Symptom relief
Last updated Jun 27, 2026 09:04 UTC
-
Exercise therapy aims to boost recovery in Bone-Weakened myeloma patients
Symptom relief Not yet recruitingThis study tests whether orthopedic check-ups and custom exercise plans can improve physical function and rehabilitation in people with multiple myeloma who have bone lesions. About 71 newly diagnosed patients will receive ongoing bone stability assessments and tailored exercise …
Sponsor: University Hospital Heidelberg • Aim: Symptom relief
Last updated Jun 27, 2026 09:01 UTC
-
Hypnosis and VR tested to calm leukemia Patients' fears
Symptom relief Not yet recruitingThis study compares hypnosis, virtual reality, and standard care to see which best reduces anxiety in adults starting chemotherapy for acute myeloid leukemia. About 99 patients will be randomly assigned to one of three groups. The goal is to find a non-drug way to help patients c…
Sponsor: University Hospital, Toulouse • Aim: Symptom relief
Last updated Jun 27, 2026 09:01 UTC
-
Can hidden blood mutations ignite heart disease?
Knowledge-focused Not yet recruitingThis study investigates clonal hematopoiesis, an age-related condition where blood stem cells acquire mutations, and how it triggers inflammation linked to heart disease. Researchers will compare immune cells from healthy people, those with high-risk mutations, and patients with …
Sponsor: VASCage GmbH • Aim: Knowledge-focused
Last updated Sep 21, 2026 20:00 UTC
-
Could you help scientists unlock genetic cancer secrets?
Knowledge-focused Not yet recruitingThis study screens up to 1,000 people with personal or family histories of certain cancers to see if they qualify for ongoing genetics research at the National Cancer Institute. Participants fill out a 15-20 minute online survey about their health and family history. No treatment…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 21, 2026 20:00 UTC
-
Why do some leukemia patients develop dangerous blood clots?
Knowledge-focused Not yet recruitingResearchers are observing adults newly diagnosed with acute leukemia during their hospital stay to learn which factors raise the risk of venous thromboembolism, a serious blood clot condition. The study follows about 250 patients from admission to discharge or death, recording cl…
Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto • Aim: Knowledge-focused
Last updated Sep 21, 2026 20:00 UTC
-
Can regional data improve bone marrow transplant results for blood cancers?
Knowledge-focused Not yet recruitingResearchers at Assiut University are studying adults with blood cancers who receive an autologous hematopoietic stem cell transplant, a procedure that uses a patient's own stem cells. The study follows 123 participants to measure survival, progression-free survival, complications…
Sponsor: Assiut University • Aim: Knowledge-focused
Last updated Sep 21, 2026 20:00 UTC
-
Can a Once-Weekly shot cut the burden of hemophilia a?
Knowledge-focused Not yet recruitingResearchers are studying how switching to efanesoctocog alfa (ALTUVOCT), a long-acting factor VIII therapy given once a week, affects adults and children with severe or moderate hemophilia A in routine care. The study tracks factor use, treatment satisfaction, and quality of life…
Sponsor: Nantes University Hospital • Aim: Knowledge-focused
Last updated Sep 21, 2026 20:00 UTC
-
Blood test may reveal why some MDS patients feel worn out on luspatercept
Knowledge-focused Not yet recruitingResearchers are studying blood samples from 150 adults with lower-risk myelodysplastic syndromes (MDS) who receive luspatercept, a drug that boosts red blood cell production. The goal is to find metabolites and other biomarkers linked to fatigue, a common side effect of the treat…
Phase 4 • Sponsor: University Hospital, Grenoble • Aim: Knowledge-focused
Last updated Sep 21, 2026 20:00 UTC
-
New study to define healthy blood clotting ranges for kids
Knowledge-focused Not yet recruitingThis study will measure normal blood clotting values in 240 children under 18 who are having surgery or a procedure with anesthesia. The goal is to establish reference ranges for the Quantra system, a device that checks how well blood clots. This information will help doctors bet…
Sponsor: HemoSonics LLC • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
Cheap blood count ratios eyed as window into Myeloma's inflammatory grip
Knowledge-focused Not yet recruitingMultiple myeloma is a blood cancer in which abnormal plasma cells build up in bone marrow, and inflammation may shape how the disease behaves. Researchers at Assiut University plan to study 60 people newly diagnosed with myeloma before any anti-myeloma treatment begins. They will…
Sponsor: Assiut University • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
Scientists to examine liver tissue after gene therapy for hemophilia
Knowledge-focused Not yet recruitingThis observational study will take small liver samples from 8 adults with hemophilia A or B who had gene therapy at least 6 months ago. Researchers want to see how the gene therapy affected liver cells, including how many cells still carry the therapy and whether there is any liv…
Sponsor: St. Jude Children's Research Hospital • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
New study tracks hidden dangers of common leukemia drug
Knowledge-focused Not yet recruitingThis study will follow 200 children with acute lymphoblastic leukemia or lymphoma to learn more about the short- and long-term side effects of asparaginase drugs. Researchers will track how often serious toxicities occur during standard treatment and a newer therapy called SJALL2…
Sponsor: St. Jude Children's Research Hospital • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
Do social factors decide who completes lymphoma treatment?
Knowledge-focused Not yet recruitingResearchers are examining health records from adults diagnosed with diffuse large B-cell lymphoma, a fast-growing blood cancer, across multiple UK hospitals. The study asks whether a patient's ethnicity, level of socioeconomic deprivation, and other health conditions influence ho…
Sponsor: The Royal Wolverhampton Hospitals NHS Trust • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
New study aims to uncover hidden danger in stem cell transplants
Knowledge-focused Not yet recruitingThis study will follow 85 adults receiving stem cell transplants to track a serious but often missed complication called TA-TMA. Researchers want to find out how common it is and how it affects survival. Participants will provide blood samples and have standard follow-up care.
Sponsor: Manuel Ricardo Espinoza-Gutarra • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Real-World data sought on myeloma drug combo
Knowledge-focused Not yet recruitingThis study will review medical records of 300 UK patients with newly diagnosed multiple myeloma who cannot have a stem cell transplant and are treated with a three-drug combination (daratumumab, lenalidomide, and dexamethasone). The goal is to see how well this therapy works in e…
Sponsor: The Royal Wolverhampton Hospitals NHS Trust • Aim: Knowledge-focused
Last updated Sep 17, 2026 00:00 UTC
-
Are CLL patients getting fair referrals? new study investigates
Knowledge-focused Not yet recruitingThis study surveys primary care doctors and nurse specialists in the West Midlands to understand how they decide to refer patients with chronic lymphocytic leukemia (CLL) to specialists. The goal is to identify differences in referral practices and find ways to make care more equ…
Sponsor: The Royal Wolverhampton Hospitals NHS Trust • Aim: Knowledge-focused
Last updated Sep 17, 2026 00:00 UTC
-
Could metabolic syndrome shape the course of rare blood cancers?
Knowledge-focused Not yet recruitingResearchers at Assiut University are studying whether metabolic syndrome, a cluster of conditions like high blood pressure and high blood sugar, relates to the clinical course of chronic Philadelphia-negative myeloproliferative neoplasms. These are rare blood cancers where the bo…
Sponsor: Assiut University • Aim: Knowledge-focused
Last updated Sep 13, 2026 00:00 UTC
-
Can a light cap boost brain power in kids with sickle cell?
Knowledge-focused Not yet recruitingThis study tests whether shining a special light on the head (transcranial photobiomodulation) can improve oxygen use and thinking skills in children with sickle cell disease. The brain needs steady oxygen, but sickle cell can reduce blood flow. Researchers will randomly assign 6…
Sponsor: St. Jude Children's Research Hospital • Aim: Knowledge-focused
Last updated Sep 12, 2026 00:00 UTC
-
Wearable patches could spot heart danger hiding in cancer treatment
Knowledge-focused Not yet recruitingThis pilot study is testing whether wearable patch monitors can help detect heart problems early in adults undergoing treatment for breast cancer, blood cancers, or multiple myeloma. Participants will wear two patches—one that tracks heart rhythm continuously and another that rec…
Sponsor: University of Minnesota • Aim: Knowledge-focused
Last updated Sep 12, 2026 00:00 UTC
-
VR pain relief for kids: scientists scan brains to see how it works
Knowledge-focused Not yet recruitingThis study will use a special brain scanner to see how virtual reality (VR) affects pain in children aged 6-17 with burns. Four children will have their brain activity measured during burn dressing changes, both with and without VR. The goal is to find brain markers that show whe…
Sponsor: Nationwide Children's Hospital • Aim: Knowledge-focused
Last updated Sep 11, 2026 00:00 UTC
-
Can three routine blood ratios predict who survives AML?
Knowledge-focused Not yet recruitingResearchers at Assiut University Hospitals are studying whether three blood measures predict survival in adults newly diagnosed with non-M3 acute myeloid leukemia. The measures are the ratio of C-reactive protein to albumin, the ratio of albumin to fibrinogen, and the level of fe…
Sponsor: Assiut University • Aim: Knowledge-focused
Last updated Sep 11, 2026 00:00 UTC
-
MRI scans may reveal hidden clues to myeloma relapse risk
Knowledge-focused Not yet recruitingThis study is looking at whether a special type of whole-body MRI can help predict how well people with multiple myeloma will do after a stem cell transplant. The MRI measures changes in bone marrow and fat content in the bones, which might indicate if the cancer is more likely t…
Sponsor: Fondazione EMN Italy Onlus • Aim: Knowledge-focused
Last updated Sep 11, 2026 00:00 UTC
-
Rare lymphoma study aims to unlock secrets of treatment success
Knowledge-focused Not yet recruitingThis study will gather information from 100 people with a rare type of lymphoma called systemic anaplastic large cell lymphoma (sALCL) who have been treated with a drug combination called BV-CHP. Researchers want to see how well the treatment works in real life and understand why…
Sponsor: Fondazione Italiana Linfomi - ETS • Aim: Knowledge-focused
Last updated Sep 11, 2026 00:00 UTC
-
Immune 'hotness' and growth markers may sharpen lymphoma prognosis
Knowledge-focused Not yet recruitingThis study examines tissue samples from 70 people with diffuse large B-cell lymphoma and other aggressive B-cell lymphomas. Researchers will measure immune cell infiltration, called tumor 'hotness', and the Ki-67 proliferation index using two scoring methods. The goal is to see i…
Sponsor: Sohag University • Aim: Knowledge-focused
Last updated Sep 06, 2026 00:00 UTC
-
Can blood tests predict transplant complications?
Knowledge-focused Not yet recruitingThis study looks at how levels of immune-signaling molecules called cytokines change in the blood just before and after a stem cell transplant. Researchers want to see if these patterns differ based on the patient's disease, such as myelofibrosis or acute leukemia, and the type o…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Sep 06, 2026 00:00 UTC
-
New study aims to predict deadly infections in blood cancer patients
Knowledge-focused Not yet recruitingThis study looks at blood cancer patients who carry drug-resistant bacteria in their gut. Researchers want to find out who is most likely to get a serious infection from these bacteria. They will collect rectal swabs and track patients for 90 days to build a prediction tool. The …
Sponsor: Fundación Pública Andaluza para la gestión de la Investigación en Sevilla • Aim: Knowledge-focused
Last updated Sep 05, 2026 00:00 UTC
-
Chemotherapy at home for leukemia: a feasibility test
Knowledge-focused Not yet recruitingThis study explores whether patients with acute myeloid leukemia can receive intravenous cytarabine chemotherapy at home instead of in the hospital. Researchers will track how many patients complete the planned home treatment, how often doses are given at home versus the hospital…
Sponsor: Zealand University Hospital • Aim: Knowledge-focused
Last updated Sep 05, 2026 00:00 UTC
-
Stem cell harvest trial aims to unlock gene therapy for rare blood disorders
Knowledge-focused Not yet recruitingThis early-phase study at St. Jude Children's Research Hospital will test whether it is safe and possible to collect blood stem cells from 12 young adults with inherited bone marrow failure syndromes. Participants will receive two drugs (filgrastim and plerixafor) to move stem ce…
Phase 1 • Sponsor: St. Jude Children's Research Hospital • Aim: Knowledge-focused
Last updated Sep 02, 2026 00:00 UTC
-
What does thalassemia really cost children and families?
Knowledge-focused Not yet recruitingThis study measures the clinical, economic, and psychosocial burden of thalassemia in children and adolescents in Sohag, Egypt. Researchers will track hospital visits, blood transfusions, and complications, and estimate direct medical costs plus indirect costs like missed school …
Sponsor: Randa Elham Hamam • Aim: Knowledge-focused
Last updated Sep 02, 2026 00:00 UTC
-
Can GLP-1 drugs improve heart function during exercise in Obesity-Related heart failure?
Knowledge-focused Not yet recruitingThis observational study follows people with obesity-related heart failure to see how their heart performs during exercise, using stress echocardiography. It observes those who are taking GLP-1/GIP receptor agonists (like semaglutide or tirzepatide) as part of their routine care,…
Sponsor: Miedziowe Centrum Zdrowia SA • Aim: Knowledge-focused
Last updated Aug 28, 2026 00:00 UTC
-
Can biological signals explain mastocytosis symptoms?
Knowledge-focused Not yet recruitingThis study aims to understand how symptoms of indolent systemic mastocytosis relate to biological signals in the body. Researchers will collect samples and data from 25 participants over 12 weeks to see how different treatments affect these signals. The goal is to improve underst…
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Aug 20, 2026 00:00 UTC
-
Blood tests could reveal who benefits from Next-Gen lymphoma antibodies
Knowledge-focused Not yet recruitingThis observational study is looking at whether biological markers in blood, tumor tissue, and imaging scans can predict how well patients with B-cell non-Hodgkin lymphoma respond to treatment with novel monoclonal antibodies. Researchers will collect samples from about 1,000 adul…
Sponsor: Fondazione Italiana Linfomi - ETS • Aim: Knowledge-focused
Last updated Aug 19, 2026 00:00 UTC
-
Ultrasound may spot silent joint damage in mild hemophilia
Knowledge-focused Not yet recruitingThis study uses ultrasound to examine the joints of adults with mild hemophilia, a group that often goes understudied. Researchers will scan six joints (ankles, knees, elbows) to look for early signs of damage that may not cause symptoms yet. The goal is to see how common joint p…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Aug 19, 2026 00:00 UTC
-
Can 3D-Printed models unlock personalized blood cancer therapies?
Knowledge-focused Not yet recruitingThis study aims to create 3D models of B-cell cancers—like chronic lymphocytic leukemia, splenic marginal-zone lymphoma, and hairy cell leukemia—using blood samples from patients. The goal is to build realistic models that mimic the tumor environment, which could help researchers…
Sponsor: IRCCS San Raffaele • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC
-
Rethinking anemia: does blood hemoglobin tell the whole story?
Knowledge-focused Not yet recruitingThis study asks whether the standard blood hemoglobin concentration accurately reflects the body's true oxygen-carrying capacity in adults with non-life-threatening anemia arriving at the emergency department. Participants will undergo additional tests, including a carbon monoxid…
Sponsor: Hospices Civils de Lyon • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
Can a smart tool keep watch on leukemia after treatment stops?
Knowledge-focused Not yet recruitingThis study explores whether a digital tool can help monitor adults with chronic myeloid leukemia who have stopped treatment for up to two years. Over 12 months, researchers will track how often patients use the tool, aiming for a usage rate of at least 60%. The goal is to see if …
Sponsor: Versailles Hospital • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
Engineering immune cells to outsmart Leukemia's defenses
Knowledge-focused Not yet recruitingThis study investigates how to engineer T cells to more effectively target acute myeloid leukemia (AML). Researchers will analyze samples from healthy donors and AML patients to identify T-cell receptors that recognize leukemia cells. The goal is to create next-generation enginee…
Sponsor: IRCCS San Raffaele • Aim: Knowledge-focused
Last updated Aug 08, 2026 00:03 UTC
-
Malaria drug combo under microscope: safety first
Knowledge-focused Not yet recruitingThis early-stage trial will give 24 healthy adults three different malaria drugs—piperaquine, pyronaridine, and artesunate—alone and together to see how they interact. Researchers will measure drug levels in the blood and watch for side effects. The goal is to learn about safety …
Phase 1 • Sponsor: University of Oxford • Aim: Knowledge-focused
Last updated Aug 07, 2026 00:00 UTC
-
Could a protein blocker quiet Leukemia's alarm system?
Knowledge-focused Not yet recruitingThis study investigates whether blocking a protein called IRAK4 can disrupt TLR signaling in leukemia cells from people with chronic lymphocytic leukemia (CLL). Researchers will collect extra blood samples from 50 adults with CLL during routine blood tests. In the lab, they will …
Sponsor: IRCCS San Raffaele • Aim: Knowledge-focused
Last updated Aug 06, 2026 00:00 UTC
-
New catheter device tested for stubborn leg vein blockages
Knowledge-focused Not yet recruitingThis observational study will track 87 people who are already scheduled to receive treatment with the Recana Thrombectomy Catheter System for blocked veins in their legs. The goal is to see how safe the device is and how well it works at clearing the blockages during the procedur…
Sponsor: Intervene, Inc. • Aim: Knowledge-focused
Last updated Aug 05, 2026 00:00 UTC
-
Does CAR-T therapy affect the brain? a study investigates
Knowledge-focused Not yet recruitingThis study follows people with relapsed or refractory multiple myeloma who are scheduled to receive BCMA CAR-T therapy, a type of cell treatment. Researchers will test memory, attention, and other thinking skills at the start and again at 1, 6, and 12 months after the infusion. T…
Sponsor: Wake Forest University Health Sciences • Aim: Knowledge-focused
Last updated Aug 02, 2026 00:00 UTC
-
Can a Child's own words improve cancer care?
Knowledge-focused Not yet recruitingThis study asks whether a simple questionnaire, called SSPedi, can capture the symptoms that children with brain or spinal cord tumors experience while on new cancer therapies. Children aged 2 to 18 who are already part of a larger French study (SACHA) will use an app to report t…
Sponsor: Assistance Publique Hopitaux De Marseille • Aim: Knowledge-focused
Last updated Aug 02, 2026 00:00 UTC
-
Protein clues in kidney disease could predict anemia and heart risks
Knowledge-focused Not yet recruitingThis study examines how the severity of chronic kidney disease (CKD) affects the breakdown of a protein called FGF23, which is linked to bone health, anemia, and heart problems. Researchers will measure different forms of FGF23 in blood samples from 80 men with CKD stages 3a to 5…
Sponsor: Centre Hospitalier Universitaire de Saint Etienne • Aim: Knowledge-focused
Last updated Aug 02, 2026 00:00 UTC
-
A simple Note-Taking change could transform blood cancer care
Knowledge-focused Not yet recruitingThis quality improvement initiative tests whether a standardized electronic medical record template for progress notes, combined with a pharmacist-led medication titration service, can improve the management of polycythemia vera (PV). The study enrolls hematologists and oncologis…
Sponsor: Massachusetts General Hospital • Aim: Knowledge-focused
Last updated Jul 31, 2026 00:00 UTC
-
Can a simple survey uncover hidden links between stress, substance use, and mental health in medical trainees?
Knowledge-focused Not yet recruitingThis study uses an anonymous online questionnaire to examine how medical students, midwifery students, and academic hospital staff use substances like alcohol, tobacco, and stimulants, and how these behaviors relate to mental health, stress, and social factors. The goal is to ide…
Sponsor: University Hospital, Strasbourg, France • Aim: Knowledge-focused
Last updated Jul 25, 2026 00:00 UTC
-
AI to predict heart damage from cancer treatments in major european study
Knowledge-focused Not yet recruitingThis study will collect data from up to 10,000 cancer patients across Europe to create better tools for predicting heart damage caused by certain cancer treatments. Researchers will use artificial intelligence alongside standard methods to develop risk scores that doctors can use…
Sponsor: University Hospital, Caen • Aim: Knowledge-focused
Last updated Jul 24, 2026 00:00 UTC
-
New cancer trial aims to crack the code of who benefits from immunotherapy
Knowledge-focused Not yet recruitingThis study enrolls 275 people with advanced solid tumors to test a new approach: using a rapid, detailed analysis of each patient's tumor and immune system to guide treatment choices. The goal is to improve the success rate of immunotherapy, which currently helps only 20-30% of p…
Phase 2 • Sponsor: UNICANCER • Aim: Knowledge-focused
Last updated Jul 23, 2026 00:00 UTC
-
CAR-T breakthroughs come with infection risks – new study aims to decode them
Knowledge-focused Not yet recruitingThis study follows adults with multiple myeloma or B-cell lymphoma who receive CAR-T cell therapy, a powerful immune treatment. Researchers track infections that occur in the first year after treatment, looking at how common they are, what causes them, and which factors raise the…
Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna • Aim: Knowledge-focused
Last updated Jul 22, 2026 00:00 UTC
-
Could a simple blood test predict lupus in children with ITP?
Knowledge-focused Not yet recruitingThis study looks at children with immune thrombocytopenic purpura (ITP) who also have certain antibodies, as they are at higher risk of developing lupus. Researchers will analyze blood samples to track immune cell changes and markers that may signal the transition to lupus. The g…
Sponsor: University Hospital, Bordeaux • Aim: Knowledge-focused
Last updated Jul 19, 2026 00:00 UTC
-
Could interferon be a hidden trigger of blood clot damage after transplant?
Knowledge-focused Not yet recruitingThis study investigates how interferon and complement proteins contribute to thrombotic microangiopathy (TMA), a serious condition involving small blood clots and organ damage that can occur after stem cell transplants. Researchers will measure interferon levels, complement activ…
Sponsor: Sofie Dhaese • Aim: Knowledge-focused
Last updated Jul 17, 2026 00:00 UTC
-
Blood cancer patients may need higher antibiotic doses to beat superbugs
Knowledge-focused Not yet recruitingThis study looks at whether the standard dose of the antibiotic ceftazidime-avibactam reaches high enough levels in the blood of people with blood cancers or those who have had a stem cell transplant. These patients are at high risk for severe infections from drug-resistant bacte…
Sponsor: Sizhou Feng • Aim: Knowledge-focused
Last updated Jul 16, 2026 00:00 UTC
-
Platelet transfusions may influence blood vessel health in critically ill patients
Knowledge-focused Not yet recruitingThis study investigates how platelet transfusions affect the function of small blood vessels and inflammation in intensive care patients with low platelet counts. Researchers measure blood vessel response using a laser device on the skin and track levels of various biomarkers in …
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC
-
New study aims to uncover why ECMO patients bleed
Knowledge-focused Not yet recruitingThis study looks at how well platelets work in patients on a life-support machine called ECMO, which helps people with severe lung or heart problems. The goal is to understand why these patients often have dangerous bleeding. Researchers will measure platelet function over time a…
Sponsor: University Hospital, Toulouse • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
New study examines belantamab combos for myeloma relapse
Knowledge-focused Not yet recruitingThis observational study will review medical records of about 100 adults with multiple myeloma that has returned after initial treatment. Researchers want to see how well belantamab mafodotin given with other drugs (bortezomib and dexamethasone, or pomalidomide and dexamethasone)…
Sponsor: PETHEMA Foundation • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:03 UTC
-
Brain fog after lymphoma: study probes lasting cognitive effects of chemotherapy
Knowledge-focused Not yet recruitingThis study looks at thinking skills, memory, and quality of life in people who are 3 to 5 years past successful treatment for Hodgkin lymphoma or certain types of B-cell lymphoma. Participants take a series of tests and questionnaires once during a regular follow-up visit. The go…
Sponsor: Fondazione Italiana Linfomi - ETS • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
New study to reveal hidden immune effects of common leukemia drug
Knowledge-focused Not yet recruitingThis study will observe 10 adults with acute myeloid leukemia who are receiving the drug gilteritinib after a stem cell transplant. Researchers want to understand how gilteritinib affects the behavior, metabolism, and function of immune cells like T-cells and monocytes. The goal …
Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Blood test could predict bleeding risk in cancer patients
Knowledge-focused Not yet recruitingThis study aims to create a score that uses a special blood test to predict bleeding risk in people with blood cancers and very low platelet counts. Researchers will take an extra blood sample from 410 participants and analyze it with viscoelastometric tests. The goal is to ident…
Sponsor: Centre Hospitalier Annecy Genevois • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Can a sedative improve blood flow in septic shock? a pilot study investigates
Knowledge-focused Not yet recruitingThis study looks at how the sedative dexmedetomidine affects the smallest blood vessels in people with septic shock, a life-threatening condition caused by severe infection. Researchers will measure blood flow in the tongue's tiny vessels and other key blood pressure indicators b…
Sponsor: First Affiliated Hospital of Wannan Medical College • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Could a Plant-Derived drug improve blood flow in septic shock?
Knowledge-focused Not yet recruitingThis pilot study will test a drug called anisodamine in 20 adults with septic shock who are on a ventilator. The goal is to see if the drug can improve blood flow in small blood vessels and help with a phenomenon called 'vascular waterfall.' This is a very early study to gather i…
Sponsor: First Affiliated Hospital of Wannan Medical College • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
New study aims to decode PTCL by genetic subtype
Knowledge-focused Not yet recruitingThis study will follow 1000 people diagnosed with peripheral T-cell lymphoma (PTCL) to see how different genetic subtypes affect disease progression and treatment response. Researchers will collect data from multiple hospitals and use genetic testing to classify patients. The goa…
Sponsor: Ruijin Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
French biobank aims to unlock secrets of rare brain vessel diseases
Knowledge-focused Not yet recruitingThis study will collect blood samples and medical information from 600 adults with rare diseases affecting blood vessels in the brain and eye, such as CADASIL and cavernous angioma. The goal is to create a long-term biobank that researchers can use to find biomarkers and better u…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
New study aims to track dangerous infections in kids with sickle cell disease
Knowledge-focused Not yet recruitingThis study will look at medical records of 350 children with sickle cell disease in France who had serious bacterial infections between 2020 and 2025. The goal is to find out which bacteria are causing these infections today, especially with new vaccines available. The results co…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:08 UTC
-
Can blood tests and scans track lymphoma in real time? new study aims to find out.
Knowledge-focused Not yet recruitingThis study will test whether doctors can quickly and accurately monitor minimal residual disease (tiny amounts of cancer left after treatment) in people with aggressive B-cell lymphoma. Researchers will use blood tests to look for tumor DNA and PET scans to see if results can be …
Sponsor: The Lymphoma Academic Research Organisation • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:08 UTC
-
New study tests if SPECT imaging can forecast prostate cancer treatment success
Knowledge-focused Not yet recruitingThis study will look at whether SPECT scans taken after Lu-PSMA therapy can help predict how well patients with metastatic castration-resistant prostate cancer (mCRPC) are doing. Researchers will measure tumor activity and volume on the scans and compare them to standard PET-base…
Sponsor: Central Hospital, Nancy, France • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
New blood test may predict bleeding risk after heart surgery
Knowledge-focused Not yet recruitingThis study looks at whether a new test called T-TAS can help predict bleeding after heart surgery. Researchers will take blood samples from 30 adults before, right after, and 24 hours after surgery. They will compare T-TAS results with standard tests and track how much bleeding a…
Sponsor: Hospital de la Santa creu i Sant Pau - Barcelona • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
Scientists hunt for clues to chemo resistance in blood cancer
Knowledge-focused Not yet recruitingThis study collects blood and bone marrow samples from 80 people with B-cell non-Hodgkin lymphoma to explore why some cancers resist chemotherapy. Researchers will analyze the tumor and its environment, and develop lab models to test new treatments. The goal is to uncover resista…
Sponsor: Nantes University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:06 UTC
-
New study aims to crack the code of treatment resistance in lymphoma
Knowledge-focused Not yet recruitingThis study will follow 70 adults with relapsed or refractory B-cell non-Hodgkin lymphoma who are receiving bispecific antibody therapy. Researchers want to understand why some patients don't respond or develop serious side effects. They will look at tumor samples, gut bacteria, a…
Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
Blood condition may predict worse outcomes after heart attack
Knowledge-focused Not yet recruitingThis study investigates whether a condition called clonal hematopoiesis of indeterminate potential (CHIP), which is an age-related change in blood cells, is linked to more severe heart damage in people who have had a major heart attack (STEMI). Researchers will test blood samples…
Sponsor: Medical University Innsbruck • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
New blood test may predict cancer relapse after transplant
Knowledge-focused Not yet recruitingThis study is testing a new blood test called AlloHeme that looks for tiny traces of a patient's own cells after a stem cell transplant. The goal is to see if the test can predict whether leukemia or MDS will come back before it happens. About 400 adults who have had or will have…
Sponsor: CareDx • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:37 UTC
-
Surgeons try High-Tech goggles to map cancer before cutting
Knowledge-focused Not yet recruitingThis study tests whether a special headset (extended reality) can help surgeons plan the removal of cancer-affected lymph nodes in the neck for people with lung cancer. Ten patients will have their PET and CT scans combined into a 3D model that the surgeon views just before surge…
Sponsor: National Taiwan University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:34 UTC
-
Can spleen surgery shield kidneys in cirrhosis? new study aims to find out
Knowledge-focused Not yet recruitingThis study follows 30 adults with liver cirrhosis who are having their spleen removed (laparoscopic splenectomy) to treat an enlarged spleen and low blood counts. Researchers will measure kidney function before surgery and for two years after to see if the surgery helps or harms …
Sponsor: Northern Jiangsu People's Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:34 UTC
-
Spleen surgery may reshape fat levels in liver patients
Knowledge-focused Not yet recruitingThis study follows 30 adults with liver cirrhosis, an enlarged spleen, and hypersplenism who are having their spleen removed by keyhole surgery. Researchers will measure changes in cholesterol and other blood fats before surgery and for two years afterward. The goal is to learn w…
Sponsor: Northern Jiangsu People's Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:34 UTC
-
Glow of white blood cells may predict sepsis danger in ER
Knowledge-focused Not yet recruitingThis study looks at whether measuring the fluorescence of certain white blood cells (neutrophils) can help doctors quickly identify sepsis patients at risk of severe complications like organ failure or septic shock. Researchers will analyze blood samples from 492 adults in the em…
Sponsor: University Hospital, Strasbourg, France • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:33 UTC
-
Chemo's hidden legacy: study probes sperm damage in young men
Knowledge-focused Not yet recruitingThis study looks at how chemotherapy for Hodgkin lymphoma may change men's sperm DNA and affect their fertility and the health of their future children. Researchers will study sperm samples from 50 men before and after treatment to find changes in DNA packaging and chemical tags.…
Sponsor: Rennes University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:33 UTC
-
Spleen surgery may change fat levels in liver patients – study to watch
Knowledge-focused Not yet recruitingThis study follows 30 people with liver cirrhosis who need spleen surgery to treat bleeding from high blood pressure in the liver. Researchers will check their cholesterol and fat levels before and for two years after surgery. The goal is to see if the surgery improves abnormal f…
Sponsor: Northern Jiangsu People's Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:33 UTC
-
Cash for breastfeeding: a new way to boost baby health?
Knowledge-focused Not yet recruitingThis study in Côte d'Ivoire tests whether giving mothers a cash reward for breastfeeding until their child is 24 months old increases breastfeeding rates and improves child and maternal health. About 1,040 mothers will either receive the cash incentive or just educational materia…
Sponsor: Swiss Tropical & Public Health Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
New study aims to uncover hidden clues in myasthenia gravis
Knowledge-focused Not yet recruitingThis observational study will follow 40 adults with thymic abnormalities or myasthenia gravis (MG)-related antibodies to better understand how the disease develops and progresses. Researchers will analyze blood, thymus tissue, and muscle samples, along with clinical assessments, …
Sponsor: IRCCS San Raffaele • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
New study monitors infection risks in advanced myeloma drug
Knowledge-focused Not yet recruitingThis Italian registry will follow 50 adults with relapsed/refractory multiple myeloma who are receiving elranatamab as part of their standard care. The goal is to track how many infections occur during the first year of treatment. The study does not test a new drug but aims to ga…
Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
New study investigates brain fog after CAR-T and bispecific antibody therapies
Knowledge-focused Not yet recruitingThis study will follow 225 blood cancer patients receiving CAR-T therapy, bispecific antibodies, or high-dose chemotherapy with stem cell transplant. Researchers will test memory, attention, and thinking skills before treatment and up to 3 years after. The goal is to understand h…
Sponsor: Aarhus University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:26 UTC
-
Tailoring sickle cell drug doses: a new hope for nigerian patients
Knowledge-focused Not yet recruitingThis study looks at how genetic differences affect the way Nigerian sickle cell patients respond to hydroxyurea, a common treatment. Researchers will monitor 100 patients to build a computer model that predicts the best dose for each person. The goal is to reduce side effects and…
Sponsor: Ochuko Orherhe • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:26 UTC
-
Tailored clotting treatment may cut bleeding after heart surgery
Knowledge-focused Not yet recruitingThis study aims to find the best dose of a clotting drug (fibrinogen) for patients after heart surgery using a heart-lung machine. Bleeding is a common complication, and current dosing is not personalized. Researchers will take blood samples from 150 adults to understand how fibr…
Sponsor: Centre Hospitalier Universitaire de Saint Etienne • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
French study to probe alternative medicine use in blood cancer patients
Knowledge-focused Not yet recruitingThis study looks at how people with blood cancers (like leukemia, lymphoma, or myeloma) in France use complementary and alternative medicines (CAM), such as acupuncture or herbal remedies. Researchers will survey 85 patients and interview some to understand why they use these the…
Sponsor: University Hospital, Limoges • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
New study aims to unlock why some children with hemophilia reject treatment
Knowledge-focused Not yet recruitingThis observational study will follow 500 children with hemophilia A who use non-factor therapy to prevent bleeding. Researchers want to understand why some children develop antibodies against factor VIII while others do not. By studying blood and stool samples over time, they hop…
Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:10 UTC
-
Scientists hunt for clues to chemo allergies in kids with leukemia
Knowledge-focused Not yet recruitingThis study looks at why some people with acute lymphoblastic leukemia (ALL) have severe allergic reactions to the drug asparaginase. Researchers will collect blood cells from 20 patients and test them in the lab to see if certain immune cells (T cells) become overactive. The goal…
Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:07 UTC
-
Oxygen-Guided transfusions could cut unnecessary blood use in ICUs
Knowledge-focused Not yet recruitingThis study tests whether measuring oxygen levels in the blood (ScvO2) can help doctors decide more precisely when to give red blood cell transfusions to critically ill patients with anemia. The goal is to reduce unnecessary transfusions and their complications. Researchers will c…
Sponsor: Semmelweis University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:03 UTC
-
AI takes on blood clotting tests: could it outsmart the experts?
Knowledge-focused Not yet recruitingThis study will compare how well an artificial intelligence (AI) system and human experts interpret ROTEM tests, which measure blood clotting in patients undergoing surgery or in critical care. Researchers will enroll 400 adults and assess agreement on whether a clotting problem …
Sponsor: Masarykova Nemocnice v Usti nad Labem, Krajska Zdravotni a.s. • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:02 UTC
-
Kids with cancer share secrets to eating well despite chemo's taste and smell side effects
Knowledge-focused Not yet recruitingThis study will interview 30 children aged 6-17 who are undergoing chemotherapy for cancer, along with their parents, to understand how they deal with changes in taste, smell, and food texture. The goal is to learn what coping strategies families use at home and in the hospital t…
Sponsor: Centre Leon Berard • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC
-
Massive study to uncover hidden link between blood mutations and immune disorders
Knowledge-focused Not yet recruitingThis study will follow 5,000 adults with immune system problems to see if certain blood cell mutations (called clonal hematopoiesis) are linked to their condition. Researchers will track new cases of immune-related diseases over time. No treatments or drugs are tested—this is pur…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC
-
Scientists dig into old samples to unlock myeloma secrets
Knowledge-focused Not yet recruitingThis study will check if stored tissue samples from 20 people with a specific type of multiple myeloma (t(4-14)) can be used to find new biomarkers. No new treatments or tests are given. The goal is to see if the samples are good enough for research.
Sponsor: BIWAKO • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:03 UTC
-
Rare skin disease patients develop even rarer lymphoma – scientists investigate why
Knowledge-focused Not yet recruitingThis study looks at the blood immune cells of 10 adults with a rare inherited skin condition called NIPAL4 ichthyosis. Researchers want to understand why three patients with this skin disease also developed a very rare lymphoma (Sezary syndrome). By describing the normal immune c…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:02 UTC
-
New study to track brain health after CAR-T cancer treatment
Knowledge-focused Not yet recruitingThis study follows 100 adults with certain types of lymphoma who are receiving CAR-T cell therapy. Researchers will test memory, attention, and other thinking skills before treatment and at 6, 12, and 24 months after. The goal is to learn how CAR-T therapy affects brain function …
Sponsor: Fondazione Italiana Linfomi - ETS • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
Could a protein on blood cancer cells lead to a new treatment?
Knowledge-focused Not yet recruitingThis study looks at a protein called IL-1RAP found on the surface of certain blood cancer cells in myelodysplastic syndromes (MDS). Researchers want to see if this protein can be targeted by a special immune therapy called CAR-T cells. They will collect bone marrow and blood samp…
Sponsor: University Hospital, Grenoble • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:11 UTC
-
Quick diet check: can short questionnaires replace food diaries?
Knowledge-focused Not yet recruitingThis study aims to see if two short questionnaires can accurately measure how much dietary fiber and iron people eat, compared to the standard method of keeping detailed food records for five days. About 50 adults aged 18 to 65 will fill out the questionnaires and also complete 2…
Sponsor: Institute of Nutrition, Slovenia (Nutris) • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:10 UTC
-
AI tool aims to predict heart risks in rare blood disorder patients
Knowledge-focused Not yet recruitingThis study is creating an AI tool to help doctors decide the best heart treatment for people who have both immune thrombocytopenia (ITP) and coronary artery disease. Researchers will look at past patient data to build the tool, then test it on 600 new patients. The goal is to bet…
Sponsor: Xiao Hui Zhang • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:08 UTC
-
Antibiotic penetration study aims to improve infection treatment
Knowledge-focused Not yet recruitingThis study looks at how the antibiotic delafloxacin spreads through the body in 20 adults with serious skin, soft tissue, bone, or joint infections. Researchers will measure drug levels in blood and in tissues collected during surgery. The goal is to understand if the drug reache…
Sponsor: IRCCS San Raffaele • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:07 UTC
-
New study tracks brain health in kids after stem cell transplants
Knowledge-focused Not yet recruitingThis observational study will follow 100 children in Denmark who receive a stem cell transplant for blood cancer or other serious blood disorders. Researchers will test their thinking skills, physical abilities, and daily activity before the transplant and for one year after. The…
Sponsor: Rigshospitalet, Denmark • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:07 UTC
-
Can less food and fewer visits still cure malnutrition? kenya study aims to find out.
Knowledge-focused Not yet recruitingThis study tests whether giving less therapeutic food and requiring fewer clinic visits can still effectively treat severe acute malnutrition in children aged 6-59 months in Kenya. About 2,274 children will take part across 45 health facilities. The goal is to find a treatment ap…
Sponsor: International Food Policy Research Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:06 UTC
-
Growing up with hemophilia: new study tracks health habits from teen to adult
Knowledge-focused Not yet recruitingThis study follows 75 young adults with severe hemophilia who were part of an earlier study as teens. Researchers want to see if their healthcare habits change as they become adults and what factors help them stick to treatment. The goal is to understand how to support a smooth t…
Sponsor: Assistance Publique Hopitaux De Marseille • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:06 UTC
-
New model aims to prevent kidney failure in brain cancer therapy
Knowledge-focused Not yet recruitingThis study looks at 50 adults with primary central nervous system lymphoma who are receiving high-dose methotrexate, a key chemotherapy. The goal is to see if measuring the drug early in the blood can predict later kidney problems. By identifying at-risk patients sooner, doctors …
Sponsor: Assistance Publique Hopitaux De Marseille • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:04 UTC
-
New study aims to uncover hidden bleeding disorder in egyptian kids
Knowledge-focused Not yet recruitingThis study will look at how common von Willebrand disease is among children in Upper Egypt, what symptoms they have, and how they are treated. Researchers will review medical records and lab tests from 25 children aged 0-18 with suspected or confirmed VWD. The goal is to improve …
Sponsor: Assiut University • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:04 UTC
-
Sugar substitutes under scrutiny: new study targets heart risks in prediabetes
Knowledge-focused Not yet recruitingThis study looks at how artificial sweeteners (saccharin, sucralose) and a natural one (erythritol) affect blood sugar control, blood clotting, and heart disease risk in 80 adults with prediabetes. Participants will be randomly assigned to take one sweetener or water for two week…
Sponsor: Charite University, Berlin, Germany • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:00 UTC
-
Greek study to measure daily life impact of iron overload drug
Knowledge-focused Not yet recruitingThis study looks at how thalassemia patients in Greece feel day-to-day while taking a standard iron-removing medicine called deferasirox. Researchers will survey 150 adults to measure their physical and mental well-being. The goal is to understand real-world quality of life, not …
Sponsor: Elpen Pharmaceutical Co. Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:12 UTC
-
Scientists watch immune system reboot after stem cell transplants
Knowledge-focused Not yet recruitingThis study follows 65 patients getting stem cell transplants for blood cancers to see how their immune systems rebuild. Researchers will track B cells and antibody responses to vaccines before and after transplant. The goal is to improve vaccination schedules and infection protec…
Sponsor: Umeå University • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:11 UTC